<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00438</drugbank-id>
  <drugbank-id>APRD00857</drugbank-id>
  <name>Ceftazidime</name>
  <description>Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.</description>
  <cas-number>72558-82-8</cas-number>
  <unii>DZR1ENT301</unii>
  <average-mass>546.576</average-mass>
  <monoisotopic-mass>546.099138468</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Ronald C. Browning, Melvin G. Pleiss, Jr., "Crystallization process for ceftazidime derivative." U.S. Patent US4659813, issued May, 1982.</synthesis-reference>
  <indication>For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).</indication>
  <pharmacodynamics>Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms &lt;i&gt;Pseudomonas&lt;/i&gt; and &lt;i&gt;Enterobacteriaceae&lt;/i&gt;. Its activity against &lt;i&gt;Pseudomonas&lt;/i&gt; is a distinguishing feature of ceftazidime among the cephalosporins.</pharmacodynamics>
  <mechanism-of-action>The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).</mechanism-of-action>
  <toxicity>Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.</toxicity>
  <metabolism/>
  <absorption>The absorption of ceftazidime is directly proportional to the size of the dose.</absorption>
  <half-life>Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.</half-life>
  <protein-binding>&lt; 10%</protein-binding>
  <route-of-elimination>The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.</route-of-elimination>
  <volume-of-distribution/>
  <clearance>* 115 mL/min</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.</description>
    <direct-parent>Cephalosporins</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Lactams</class>
    <subclass>Beta lactams</subclass>
    <alternative-parent>1,3-thiazines</alternative-parent>
    <alternative-parent>2,4-disubstituted thiazoles</alternative-parent>
    <alternative-parent>2-amino-1,3-thiazoles</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Azetidines</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dialkylthioethers</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyridinium derivatives</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Thiohemiaminal derivatives</alternative-parent>
    <substituent>1,3-thiazol-2-amine</substituent>
    <substituent>2,4-disubstituted 1,3-thiazole</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azetidine</substituent>
    <substituent>Azole</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Cephalosporin</substituent>
    <substituent>Dialkylthioether</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Hemithioaminal</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Meta-thiazine</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridinium</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Thiazole</substituent>
    <substituent>Thioether</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001024</drugbank-id>
      <name>Ceftazidime pentahydrate</name>
      <unii>9M416Z9QNR</unii>
      <cas-number>78439-06-2</cas-number>
      <inchikey>NMVPEQXCMGEDNH-TZVUEUGBSA-N</inchikey>
      <average-mass>636.65</average-mass>
      <monoisotopic-mass>636.151962842</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001474</drugbank-id>
      <name>Ceftazidime sodium</name>
      <unii>CMC30V039K</unii>
      <cas-number>73547-61-2</cas-number>
      <inchikey>JEEWDSDYUSEQML-ROMZVAKDSA-M</inchikey>
      <average-mass>568.55</average-mass>
      <monoisotopic-mass>568.08108367</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">CAZ</synonym>
    <synonym language="german" coder="inn">Ceftazidim</synonym>
    <synonym language="spanish" coder="inn">Ceftazidima</synonym>
    <synonym language="english/french" coder="inn">Ceftazidime</synonym>
    <synonym language="english" coder="">Ceftazidime anhydrous</synonym>
    <synonym language="latin" coder="inn">Ceftazidimum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Avycaz</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-2700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA206494</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Pfizer Laboratories, Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA065482</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>500 mg/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Pfizer Laboratories, Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>500 mg/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Pfizer Laboratories, Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Pfizer Laboratories, Division of Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA065481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-28</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA065482</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-3179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-3177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-3178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>6 g/30mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>WG Critical Care, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44567-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>6 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>WG Critical Care, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44567-235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/20mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime</name>
      <labeller>WG Critical Care, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44567-236</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/20mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062640</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime and Dextrose</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0264-3143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime and Dextrose</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0264-3145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ceftazidime for Injection BP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02437848</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection BP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02437856</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection BP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02437864</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection, BP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439522</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection, USP</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00886971</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection, USP</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00886955</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceftazidime for Injection, USP</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00886963</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Inj 10gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01968092</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-11-07</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Inj 1gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01974408</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-09-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Inj 2gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01974416</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Injection - Pws Im IV 1g/vial</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215012</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-09-01</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Injection - Pws IV 10gm/vial</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02213737</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-07</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ceptaz Injection - Pws IV 2gm/vial</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215020</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-12-28</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0377</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-29</started-marketing-on>
      <ended-marketing-on>2014-04-27</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-13</started-marketing-on>
      <ended-marketing-on>2014-04-20</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-10-01</started-marketing-on>
      <ended-marketing-on>2014-02-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>170 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-10-01</started-marketing-on>
      <ended-marketing-on>2013-11-24</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-08-26</started-marketing-on>
      <ended-marketing-on>2014-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-08-13</started-marketing-on>
      <ended-marketing-on>2014-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-10-05</started-marketing-on>
      <ended-marketing-on>2013-06-15</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-10-05</started-marketing-on>
      <ended-marketing-on>2013-07-12</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-377</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>170 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>56 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>111 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on>2017-08-08</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>170 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>56 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline Manufacturing SpA</labeller>
      <ndc-id/>
      <ndc-product-code>51952-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on>2017-11-17</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>111 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-08-26</started-marketing-on>
      <ended-marketing-on>2011-02-28</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>56 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>111 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050634</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-05</started-marketing-on>
      <ended-marketing-on>2007-07-05</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>GlaxoSmithKline</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0381</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-05</started-marketing-on>
      <ended-marketing-on>2007-07-05</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>170 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Teligent Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52565-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA050578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02212218</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1 g</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02212226</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-12-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02212234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>6 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz Inj 1gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00640034</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz Inj 2gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00640042</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz Inj 500mg/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00640026</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2002-01-29</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortaz Pws Inj 6gm/vial</name>
      <labeller>Glaxo Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00791679</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2001-10-16</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira Worldwide, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5083</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-09</started-marketing-on>
      <ended-marketing-on>2007-01-09</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062662</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA062662</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>6 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA062662</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA064032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazicef</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-5093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>2 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA064032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tazidime Add-vantage Inj 1.0gm/vial</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00887129</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tazidime Add-vantage Inj 2gm/vial</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01980645</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tazidime Inj 500mg/vial</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00888338</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-03</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zavicefta</name>
      <labeller>Pfizer Ireland Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004027</ema-product-code>
      <ema-ma-number>EU/1/16/1109/001</ema-ma-number>
      <started-marketing-on>2016-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Cefzim</name>
      <company>Pharco B International</company>
    </international-brand>
    <international-brand>
      <name>Ceptaz</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Fortum</name>
      <company>GlaxoSmithKline</company>
    </international-brand>
    <international-brand>
      <name>Tazidime</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Veltadim</name>
      <company>Novell</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Zavicefta</name>
      <ingredients>Avibactam + Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime and Dextrose</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime and Dextrose</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazicef</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Avycaz</name>
      <ingredients>Avibactam + Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection BP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection BP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection BP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazidime Add-vantage Inj 1.0gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazidime Inj 500mg/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Inj 10gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Inj 1gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Inj 2gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Tazidime Add-vantage Inj 2gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Injection - Pws Im IV 1g/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Injection - Pws IV 2gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceptaz Injection - Pws IV 10gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz Inj 500mg/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz Inj 1gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz Inj 2gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Fortaz Pws Inj 6gm/vial</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection, USP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection, USP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection, USP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
    <mixture>
      <name>Ceftazidime for Injection, BP</name>
      <ingredients>Ceftazidime</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Antibioticos Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Aurobindo Pharma Ltd.</name>
      <url>http://www.aurobindo.com</url>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>BMH Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>GlaxoSmithKline Inc.</name>
      <url>http://www.gsk.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Sagent Pharmaceuticals</name>
      <url>http://www.sagentpharma.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Wockhardt Ltd.</name>
      <url>http://www.wockhardtin.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">Acs dobfar spa</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Wockhardt ltd</manufacturer>
    <manufacturer generic="false" url="">Glaxosmithkline</manufacturer>
    <manufacturer generic="false" url="">Hospira inc</manufacturer>
    <manufacturer generic="false" url="">Eli lilly and co</manufacturer>
    <manufacturer generic="false" url="">Baxter healthcare corp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Tazicef 1 gram vial</description>
      <cost currency="USD">4.57</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Ceftazidime-sodium carb powder</description>
      <cost currency="USD">6.27</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Ceftazidime 1 gm vial</description>
      <cost currency="USD">10.46</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Tazicef 2 gram vial</description>
      <cost currency="USD">10.66</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 1 gm vial</description>
      <cost currency="USD">14.23</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 1 gm add-vantage vial</description>
      <cost currency="USD">14.71</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Ceftazidime 2 gm vial</description>
      <cost currency="USD">19.97</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 1 g/vial</description>
      <cost currency="USD">25.44</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 2 gm vial</description>
      <cost currency="USD">28.45</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 2 gm add-vantage vial</description>
      <cost currency="USD">28.93</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Tazicef 6 gram vial</description>
      <cost currency="USD">29.88</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 2 g/vial</description>
      <cost currency="USD">50.01</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 6 gm vial</description>
      <cost currency="USD">82.8</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Ceftazidime 6 gm vial</description>
      <cost currency="USD">97.05</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz 6 g/vial</description>
      <cost currency="USD">150.11</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fortaz-iso-osmotic 1 gm/50 ml</description>
      <cost currency="USD">0.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Fortaz-iso-osmot 2 gm/50 ml</description>
      <cost currency="USD">0.62</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antibacterials for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>beta-Lactams</category>
      <mesh-id>D047090</mesh-id>
    </category>
    <category>
      <category>Cephaloridine</category>
      <mesh-id>D002509</mesh-id>
    </category>
    <category>
      <category>Cephalosporins</category>
      <mesh-id>D002511</mesh-id>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Lactams</category>
      <mesh-id>D007769</mesh-id>
    </category>
    <category>
      <category>Nephrotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT1/SLC22A6 inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
    <category>
      <category>Thiazines</category>
      <mesh-id>D013843</mesh-id>
    </category>
    <category>
      <category>Third-Generation Cephalosporins</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Enteric bacteria and other eubacteria</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1 g/20mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>500 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>2 g/20mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>2 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>200 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>6 g/30mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>6 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>111 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>170 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>200 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>56 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>2 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>40 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>2 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>6 g</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>1 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>6 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J01DD02">
      <level code="J01DD">Third-generation cephalosporins</level>
      <level code="J01D">OTHER BETA-LACTAM ANTIBACTERIALS</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:12.06.12</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00438.pdf?1265922794</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00438.pdf?1265922734</msds>
  <patents>
    <patent>
      <number>7112592</number>
      <country>United States</country>
      <approved>2006-09-26</approved>
      <expires>2022-02-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8178554</number>
      <country>United States</country>
      <approved>2012-05-15</approved>
      <expires>2021-07-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7612087</number>
      <country>United States</country>
      <approved>2009-11-03</approved>
      <expires>2026-11-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8471025</number>
      <country>United States</country>
      <approved>2013-06-25</approved>
      <expires>2031-08-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8835455</number>
      <country>United States</country>
      <approved>2014-09-16</approved>
      <expires>2030-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8969566</number>
      <country>United States</country>
      <approved>2015-03-03</approved>
      <expires>2032-06-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9284314</number>
      <country>United States</country>
      <approved>2016-03-15</approved>
      <expires>2032-06-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9695122</number>
      <country>United States</country>
      <approved>2017-07-04</approved>
      <expires>2032-06-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The therapeutic efficacy of Ceftazidime can be decreased when used in combination with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Ceftazidime can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Foscarnet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>Ceftazidime may increase the nephrotoxic activities of Tenofovir disoproxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Ceftazidime may increase the nephrotoxic activities of Tenofovir alafenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>Ceftazidime may increase the nephrotoxic activities of Tenofovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Phenazopyridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Clodronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Tiludronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Incadronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>Icosapent may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>Cefotiam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>Cefmenoxime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>Cefmetazole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Cidofovir may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>Cefpiramide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Ceftazidime may decrease the excretion rate of Leuprolide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Ceftazidime may decrease the excretion rate of Goserelin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Ceftazidime may decrease the excretion rate of Salmon Calcitonin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Ceftazidime may decrease the excretion rate of Desmopressin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Ceftazidime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Ceftazidime may decrease the excretion rate of Tositumomab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Ceftazidime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Folic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Ceftazidime may decrease the excretion rate of Pyridoxine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Ceftazidime may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Ceftazidime may decrease the excretion rate of Amphetamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Ceftazidime may decrease the excretion rate of Cevimeline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Lorazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Ceftazidime may decrease the excretion rate of Carbidopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>Ceftazidime may decrease the excretion rate of Tramadol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Ceftazidime may decrease the excretion rate of Fluconazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Ceftazidime may decrease the excretion rate of Oseltamivir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Ceftazidime may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Ceftazidime may decrease the excretion rate of Reserpine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ceftazidime may decrease the excretion rate of Ticlopidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Ceftazidime may decrease the excretion rate of Pantoprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Ceftazidime may decrease the excretion rate of Gadodiamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Ceftazidime may decrease the excretion rate of Pregabalin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Temazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Ceftazidime may decrease the excretion rate of Milrinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Ceftazidime may decrease the excretion rate of Butabarbital which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>Ceftazidime may decrease the excretion rate of Ranolazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Ceftazidime may decrease the excretion rate of Benzatropine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Ceftazidime may decrease the excretion rate of Doxycycline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Ceftazidime may decrease the excretion rate of Carmustine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Ceftazidime may decrease the excretion rate of Metoprolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Ceftazidime may decrease the excretion rate of Isradipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Ceftazidime may decrease the excretion rate of Diatrizoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Ceftazidime may decrease the excretion rate of Topiramate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Ceftazidime may decrease the excretion rate of Liothyronine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Ceftazidime may decrease the excretion rate of Disopyramide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Ceftazidime may decrease the excretion rate of Acarbose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Ceftazidime may decrease the excretion rate of Venlafaxine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Ceftazidime may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Ceftazidime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Ceftazidime may decrease the excretion rate of Bleomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Ceftazidime may decrease the excretion rate of Etomidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Ceftazidime may decrease the excretion rate of Etonogestrel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ceftazidime may decrease the excretion rate of Ropivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Ceftazidime may decrease the excretion rate of Ertapenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Ceftazidime may decrease the excretion rate of Ibutilide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Ceftazidime may decrease the excretion rate of Pentobarbital which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Ceftazidime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Ceftazidime may decrease the excretion rate of Piperacillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Ceftazidime may decrease the excretion rate of Floxuridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Ceftazidime may decrease the excretion rate of Tolcapone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Ceftazidime may decrease the excretion rate of Nitroprusside which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>Ceftazidime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Ceftazidime may decrease the excretion rate of Ethambutol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Ceftazidime may decrease the excretion rate of Metformin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Ceftazidime may decrease the excretion rate of Methadone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Ceftazidime may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>Ceftazidime may decrease the excretion rate of Cetirizine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>Ceftazidime may decrease the excretion rate of Clobazam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Ceftazidime may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Ceftazidime may decrease the excretion rate of Aztreonam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Ceftazidime may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Ceftazidime may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Ceftazidime may decrease the excretion rate of Clozapine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Ceftazidime may decrease the excretion rate of Sucralfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Ceftazidime may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Ceftazidime may decrease the excretion rate of Timolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Ceftazidime may decrease the excretion rate of Palonosetron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Ceftazidime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Ceftazidime may decrease the excretion rate of Sorafenib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Ceftazidime may decrease the excretion rate of Nisoldipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Ceftazidime may decrease the excretion rate of Eszopiclone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Ceftazidime may decrease the excretion rate of Alprazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Ceftazidime may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Ceftazidime may decrease the excretion rate of Pramipexole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Ceftazidime may decrease the excretion rate of Ampicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Ceftazidime may decrease the excretion rate of Secobarbital which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Ceftazidime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Ceftazidime may decrease the excretion rate of Trifluridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Ceftazidime may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Ceftazidime may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>Ceftazidime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Ceftazidime may decrease the excretion rate of Gemcitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Ceftazidime may decrease the excretion rate of Duloxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Ceftazidime may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Ceftazidime may decrease the excretion rate of Lenalidomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>Ceftazidime may decrease the excretion rate of Buspirone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Ceftazidime may decrease the excretion rate of Fosinopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Ceftazidime may decrease the excretion rate of Flutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Ceftazidime may decrease the excretion rate of Cimetidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Ceftazidime may decrease the excretion rate of Haloperidol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Ceftazidime may decrease the excretion rate of Metolazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Ceftazidime may decrease the excretion rate of Cefdinir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Ceftazidime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Azelaic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Ceftazidime may decrease the excretion rate of Pentostatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Ceftazidime may decrease the excretion rate of Methoxsalen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Ceftazidime may decrease the excretion rate of Piroxicam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Ceftazidime may decrease the excretion rate of Lamotrigine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Ceftazidime may decrease the excretion rate of Zanamivir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Ceftazidime may decrease the excretion rate of Methotrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Ceftazidime may decrease the excretion rate of Cephalexin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Ceftazidime may decrease the excretion rate of Fondaparinux which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Ceftazidime may decrease the excretion rate of Propranolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Ceftazidime may decrease the excretion rate of Valaciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>Ceftazidime may decrease the excretion rate of Levocarnitine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Ceftazidime may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Ceftazidime may decrease the excretion rate of Gadoteridol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Ceftazidime may decrease the excretion rate of Labetalol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Ceftazidime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Ceftazidime may decrease the excretion rate of Chloroquine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Ceftazidime may decrease the excretion rate of Bisoprolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Ceftazidime may decrease the excretion rate of Testosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Ceftazidime may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Ceftazidime may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Ceftazidime may decrease the excretion rate of Prednisone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Ceftazidime may decrease the excretion rate of Dyphylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Ceftazidime may decrease the excretion rate of Mecamylamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Ceftazidime may decrease the excretion rate of Metaxalone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>Ceftazidime may decrease the excretion rate of Verapamil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Ceftazidime may decrease the excretion rate of Nilutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Ceftazidime may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Ceftazidime may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Ceftazidime may decrease the excretion rate of Galantamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Ceftazidime may decrease the excretion rate of Midazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Ceftazidime may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Flurazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Ceftazidime may decrease the excretion rate of Phentolamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Ceftazidime may decrease the excretion rate of Furosemide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Ceftazidime may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Ceftazidime may decrease the excretion rate of Tamsulosin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Ceftazidime may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Ceftazidime may decrease the excretion rate of Flurbiprofen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Ceftazidime may decrease the excretion rate of Oxacillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Ceftazidime may decrease the excretion rate of Nedocromil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Ceftazidime may decrease the excretion rate of Lisinopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Ceftazidime may decrease the excretion rate of Thiabendazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Ceftazidime may decrease the excretion rate of Nateglinide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Ceftazidime may decrease the excretion rate of Pralidoxime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Ceftazidime may decrease the excretion rate of Etodolac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Ceftazidime may decrease the excretion rate of Tetracycline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Ceftazidime may decrease the excretion rate of Meropenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Ceftazidime may decrease the excretion rate of Methimazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Ceftazidime may decrease the excretion rate of Tirofiban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Ceftazidime may decrease the excretion rate of Phenelzine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Ceftazidime may decrease the excretion rate of Propantheline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Ceftazidime may decrease the excretion rate of Estradiol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Ceftazidime may decrease the excretion rate of Acyclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Ceftazidime may decrease the excretion rate of Perindopril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Ceftazidime may decrease the excretion rate of Fenoldopam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Ceftazidime may decrease the excretion rate of Dicyclomine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Ceftazidime may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Ceftazidime may decrease the excretion rate of Indapamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Ceftazidime may decrease the excretion rate of Ribavirin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Ceftazidime may decrease the excretion rate of Tadalafil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Ceftazidime may decrease the excretion rate of Fosfomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Diazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Ceftazidime may decrease the excretion rate of Cefaclor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Ceftazidime may decrease the excretion rate of Tolazamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Ceftazidime may decrease the excretion rate of Dobutamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Oxazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Ceftazidime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Ceftazidime may decrease the excretion rate of Temozolomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Ceftazidime may decrease the excretion rate of Diflunisal which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>Ceftazidime may decrease the excretion rate of Ranitidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Ceftazidime may decrease the excretion rate of Terbutaline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Ceftazidime may decrease the excretion rate of Bumetanide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Ceftazidime may decrease the excretion rate of Testolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Ceftazidime may decrease the excretion rate of Triazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Ceftazidime may decrease the excretion rate of Didanosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Ceftazidime may decrease the excretion rate of Zonisamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Ceftazidime may decrease the excretion rate of Tinidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Ceftazidime may decrease the excretion rate of Amantadine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Ceftazidime may decrease the excretion rate of Almotriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Ceftazidime may decrease the excretion rate of Azacitidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Ceftazidime may decrease the excretion rate of Maprotiline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Meclofenamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Acetylsalicylic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Ceftazidime may decrease the excretion rate of Isoniazid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Ceftazidime may decrease the excretion rate of Rizatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Ceftazidime may decrease the excretion rate of Carboplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Ceftazidime may decrease the excretion rate of Pindolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Ceftazidime may decrease the excretion rate of Mepivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Ceftazidime may decrease the excretion rate of Zaleplon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Ceftazidime may decrease the excretion rate of Methyldopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Ceftazidime may decrease the excretion rate of Ramelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Ceftazidime may decrease the excretion rate of Dopamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Ceftazidime may decrease the excretion rate of Oxaprozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Ceftazidime may decrease the excretion rate of Azathioprine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Ceftazidime may decrease the excretion rate of Auranofin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Ceftazidime may decrease the excretion rate of Salbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Ceftazidime may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>Ceftazidime may decrease the excretion rate of Ganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ceftazidime may decrease the excretion rate of Ketoprofen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Ceftazidime may decrease the excretion rate of Edrophonium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Ceftazidime may decrease the excretion rate of Metyrapone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Ceftazidime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Ceftazidime may decrease the excretion rate of Guanfacine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Ceftazidime may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Ceftazidime may decrease the excretion rate of Phylloquinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Ceftazidime may decrease the excretion rate of Topotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Ceftazidime may decrease the excretion rate of Tolterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Ceftazidime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Ceftazidime may decrease the excretion rate of Memantine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>Ceftazidime may decrease the excretion rate of Lubiprostone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Ceftazidime may decrease the excretion rate of Abacavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ceftazidime may decrease the excretion rate of Ibuprofen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Ceftazidime may decrease the excretion rate of Amoxicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Ceftazidime may decrease the excretion rate of Glipizide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Clonazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Ceftazidime may decrease the excretion rate of Promethazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Ceftazidime may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Ceftazidime may decrease the excretion rate of Flucytosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Ceftazidime may decrease the excretion rate of Capecitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Ceftazidime may decrease the excretion rate of Sibutramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Ceftazidime may decrease the excretion rate of Nifedipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Ceftazidime may decrease the excretion rate of Tolbutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Ceftazidime may decrease the excretion rate of Rabeprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Ceftazidime may decrease the excretion rate of Doxacurium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Ceftazidime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Ceftazidime may decrease the excretion rate of Cefadroxil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Ceftazidime may decrease the excretion rate of Flavoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Ceftazidime may decrease the excretion rate of Nefazodone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>Ceftazidime may decrease the excretion rate of Bupropion which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Ceftazidime may decrease the excretion rate of Trimetrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Ceftazidime may decrease the excretion rate of Cilostazol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Ceftazidime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Ceftazidime may decrease the excretion rate of Guanethidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>Ceftazidime may decrease the excretion rate of Ifosfamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>Ceftazidime may decrease the excretion rate of Naloxone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Ceftazidime may decrease the excretion rate of Nadolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Ceftazidime may decrease the excretion rate of Flumazenil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>Ceftazidime may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Ceftazidime may decrease the excretion rate of Fomepizole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Ceftazidime may decrease the excretion rate of Estazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Ceftazidime may decrease the excretion rate of Ketamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Ceftazidime may decrease the excretion rate of Budesonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Ceftazidime may decrease the excretion rate of Quetiapine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Ceftazidime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Ceftazidime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Ceftazidime may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Ceftazidime may decrease the excretion rate of Iodixanol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Ceftazidime may decrease the excretion rate of Sitagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Ceftazidime may decrease the excretion rate of Paliperidone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>Ceftazidime may decrease the excretion rate of Varenicline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Ceftazidime may decrease the excretion rate of Arformoterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Ceftazidime may decrease the excretion rate of Hydralazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Ceftazidime may decrease the excretion rate of Cefotetan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Ceftazidime may decrease the excretion rate of Cefradine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Ceftazidime may decrease the excretion rate of Penbutolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Ceftazidime may decrease the excretion rate of Rasagiline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>Ceftazidime may decrease the excretion rate of Colchicine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Ceftazidime may decrease the excretion rate of Tiotropium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Ceftazidime may decrease the excretion rate of Ceftibuten which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Ceftazidime may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Ceftazidime may decrease the excretion rate of Amrinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Ceftazidime may decrease the excretion rate of Oxybenzone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Ceftazidime may decrease the excretion rate of Allylestrenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Ceftazidime may decrease the excretion rate of Fenproporex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Ceftazidime may decrease the excretion rate of Bromazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Ceftazidime may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Ceftazidime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>Ceftazidime may decrease the excretion rate of Ketazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Ceftazidime may decrease the excretion rate of Valganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>Ceftazidime may decrease the excretion rate of Sorbitol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Ceftazidime may decrease the excretion rate of Roflumilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Ceftazidime may decrease the excretion rate of Topiroxostat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Ceftazidime may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Ceftazidime may decrease the excretion rate of Lorcaserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Ceftazidime may decrease the excretion rate of Pegaptanib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Ceftazidime may decrease the excretion rate of Milnacipran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Ceftazidime may decrease the excretion rate of Clevidipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Ceftazidime may decrease the excretion rate of Lofexidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ceftazidime may decrease the excretion rate of Ezogabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Ceftazidime may decrease the excretion rate of Migalastat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Ceftazidime may decrease the excretion rate of Brivaracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Ceftazidime may decrease the excretion rate of Apremilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Ceftazidime may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Ceftazidime may decrease the excretion rate of Ipilimumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Ceftazidime may decrease the excretion rate of Icatibant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Ceftazidime may decrease the excretion rate of Alogliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Ceftazidime may decrease the excretion rate of Prasugrel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Ceftazidime may decrease the excretion rate of Doripenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Ceftazidime may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Ceftazidime may decrease the excretion rate of Nalmefene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Ceftazidime may decrease the excretion rate of Droxidopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Ceftazidime may decrease the excretion rate of Levocetirizine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Ceftazidime may decrease the excretion rate of Saxagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Ceftazidime may decrease the excretion rate of Telavancin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>Ceftazidime may decrease the excretion rate of Prucalopride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Ceftazidime may decrease the excretion rate of Flupirtine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>Ceftazidime may decrease the excretion rate of Dalfampridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Ceftazidime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Ceftazidime may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Ceftazidime may decrease the excretion rate of Fesoterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Ceftazidime may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Ceftazidime may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Ceftazidime may decrease the excretion rate of Aceclofenac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Ceftazidime may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Ceftazidime may decrease the excretion rate of Dimercaprol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Ceftazidime may decrease the excretion rate of Mangafodipir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Ceftazidime may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Ceftazidime may decrease the excretion rate of Plerixafor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Ceftazidime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Ceftazidime may decrease the excretion rate of Tiopronin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Ceftazidime may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Ceftazidime may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Ceftazidime may decrease the excretion rate of Deferiprone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Ceftazidime may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Ceftazidime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Ceftazidime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Ceftazidime may decrease the excretion rate of Mirabegron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Ceftazidime may decrease the excretion rate of Peginesatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Ceftazidime may decrease the excretion rate of Aclidinium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>Ceftazidime may decrease the excretion rate of Enzalutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Ceftazidime may decrease the excretion rate of Teduglutide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Ceftazidime may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Ceftazidime may decrease the excretion rate of Formestane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Ceftazidime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Ceftazidime may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>Ceftazidime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Ceftazidime may decrease the excretion rate of Trametinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Ceftazidime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Ceftazidime may decrease the excretion rate of Macitentan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>Ceftazidime may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Ceftazidime may decrease the excretion rate of Gemeprost which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>Ceftazidime may decrease the excretion rate of Ledipasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Ceftazidime may decrease the excretion rate of Empagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Ceftazidime may decrease the excretion rate of Ceftolozane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Ceftazidime may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>Ceftazidime may decrease the excretion rate of Vortioxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Ceftazidime may decrease the excretion rate of Tasimelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Ceftazidime may decrease the excretion rate of Edoxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Ceftazidime may decrease the excretion rate of Idebenone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Ceftazidime may decrease the excretion rate of Vilanterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Ceftazidime may decrease the excretion rate of Benzydamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Ceftazidime may decrease the excretion rate of Trimebutine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Ceftazidime may decrease the excretion rate of Tixocortol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Ceftazidime may decrease the excretion rate of Ancestim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Ceftazidime may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Ceftazidime may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Ceftazidime may decrease the excretion rate of Pentastarch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Ceftazidime may decrease the excretion rate of Stiripentol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Ceftazidime may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Ceftazidime may decrease the excretion rate of Dienogest which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Ceftazidime may decrease the excretion rate of Chromic chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Ceftazidime may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Ceftazidime may decrease the excretion rate of Ioversol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Ceftazidime may decrease the excretion rate of Ioxilan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Ceftazidime may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Ceftazidime may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Ceftazidime may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Ceftazidime may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Ceftazidime may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Ceftazidime may decrease the excretion rate of Iopromide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Ceftazidime may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Ceftazidime may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Ceftazidime may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Ceftazidime may decrease the excretion rate of Viloxazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Ceftazidime may decrease the excretion rate of Etoperidone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Ceftazidime may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Ceftazidime may decrease the excretion rate of Arotinolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Ceftazidime may decrease the excretion rate of Moxisylyte which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Ceftazidime may decrease the excretion rate of Pholcodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Ceftazidime may decrease the excretion rate of Piracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>Ceftazidime may decrease the excretion rate of Dexketoprofen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>Ceftazidime may decrease the excretion rate of Bisoxatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Ceftazidime may decrease the excretion rate of Nicorandil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Ceftazidime may decrease the excretion rate of Blonanserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Ceftazidime may decrease the excretion rate of Melperone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Ceftazidime may decrease the excretion rate of Methylene blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Ceftazidime may decrease the excretion rate of Pirlindole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Ceftazidime may decrease the excretion rate of Toloxatone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Ceftazidime may decrease the excretion rate of Dextran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>Ceftazidime may decrease the excretion rate of Tegafur which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Ceftazidime may decrease the excretion rate of Gimeracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Ceftazidime may decrease the excretion rate of Imidafenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Ceftazidime may decrease the excretion rate of Idarucizumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Ceftazidime may decrease the excretion rate of Lixisenatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>Ceftazidime may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Ceftazidime may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Ceftazidime may decrease the excretion rate of Choline C 11 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Ceftazidime may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Ceftazidime may decrease the excretion rate of Propacetamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Ceftazidime may decrease the excretion rate of Sacubitril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Ceftazidime may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Ceftazidime may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Ceftazidime may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Ceftazidime may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Ceftazidime may decrease the excretion rate of Sulbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Ceftazidime may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Ceftazidime may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Ceftazidime may decrease the excretion rate of Mersalyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Ceftazidime may decrease the excretion rate of Invert sugar which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Ceftazidime may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Ceftazidime may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Ceftazidime may decrease the excretion rate of Sodium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Ceftazidime may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>Ceftazidime may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Ceftazidime may decrease the excretion rate of Enalaprilat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Ceftazidime may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Ceftazidime may decrease the excretion rate of Acrivastine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Ceftazidime may decrease the excretion rate of Octinoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Ceftazidime may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Ceftazidime may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>Ceftazidime may decrease the excretion rate of Ixazomib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Ceftazidime may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Ceftazidime may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Ceftazidime may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Ceftazidime may decrease the excretion rate of Selenious acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Ceftazidime may decrease the excretion rate of Opium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Ceftazidime may decrease the excretion rate of Selenium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Ceftazidime may decrease the excretion rate of Chromium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Ceftazidime may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Ceftazidime may decrease the excretion rate of Pyrantel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Ceftazidime may decrease the excretion rate of Bicisate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Ceftazidime may decrease the excretion rate of Tocopherol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>Ceftazidime may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Ceftazidime may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Ceftazidime may decrease the excretion rate of Clove oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Ceftazidime may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Ceftazidime may decrease the excretion rate of Pidotimod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Ceftazidime may decrease the excretion rate of Cefroxadine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>Ceftazidime may decrease the excretion rate of Lesinurad which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Ceftazidime may decrease the excretion rate of Etafedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Ceftazidime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Ceftazidime may decrease the excretion rate of Pitolisant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Ceftazidime may decrease the excretion rate of Naldemedine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Ceftazidime may decrease the excretion rate of Tropisetron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>Ceftazidime may decrease the excretion rate of Baricitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>Ceftazidime may decrease the excretion rate of Apalutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Ceftazidime may decrease the excretion rate of Valbenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Ceftazidime may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Ceftazidime may decrease the excretion rate of Benznidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Ceftazidime may decrease the excretion rate of Isoflavone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Ceftazidime may decrease the excretion rate of Vaborbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Ceftazidime may decrease the excretion rate of Brincidofovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Ceftazidime may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Ceftazidime may decrease the excretion rate of Propiverine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>Ceftazidime may decrease the excretion rate of Benserazide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Ceftazidime may decrease the excretion rate of Tiapride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Ceftazidime may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Ceftazidime may decrease the excretion rate of Nedaplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Ceftazidime may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Ceftazidime may decrease the excretion rate of Alclofenac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Ceftazidime may decrease the excretion rate of Inositol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Ceftazidime may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Ceftazidime may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Ceftazidime may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>Ceftazidime may decrease the excretion rate of Ipecac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Ceftazidime may decrease the excretion rate of Almasilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Ceftazidime may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Ceftazidime may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Ceftazidime may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Ceftazidime may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Ceftazidime may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Ceftazidime may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Ceftazidime may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Ceftazidime may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>Ceftazidime may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Ceftazidime may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Ceftazidime may decrease the excretion rate of Patent Blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Ceftazidime may decrease the excretion rate of Choline salicylate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Ceftazidime may decrease the excretion rate of Pentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Ceftazidime may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Ceftazidime may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Ceftazidime may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Ceftazidime may decrease the excretion rate of Chromic citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Ceftazidime may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Ceftazidime may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Ceftazidime may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Ceftazidime may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Ceftazidime may decrease the excretion rate of Solriamfetol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>Loracarbef may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>Cefalotin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>Cefotaxime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>Bacitracin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>Cephaloglycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>Adefovir dipivoxil may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Pentamidine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>Ceforanide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>Cefditoren may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Atazanavir may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>Colistimethate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>Cefuroxime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>Cefapirin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>Cefprozil may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>Cefamandole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>Cefazolin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>Cefonicid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>Cefoperazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>Cefoxitin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>Ceftizoxime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Choline magnesium trisalicylate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>Cefepime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>Cefacetrile may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>Cefpodoxime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>Antrafenine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Aminophenazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Lopinavir may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>Hydrolyzed Cephalothin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>Cephalothin Group may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Niflumic acid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>Latamoxef may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>Gentamicin C1a may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>Ceftobiprole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cimicoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>Ceftaroline fosamil may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Felbinac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>Cefaloridine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>Cefminox may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Dexibuprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Tolfenamic acid may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Firocoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>Morniflumate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Talniflumate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Robenacoxib may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>Flomoxef may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Fentiazac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Suxibuzone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>Cefatrizine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>Dibekacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>Micronomicin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Bumadizone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Alminoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Flunoxaprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Feprazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Difenpiramide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Nifenazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Lonazolac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>Cefcapene may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>Cefodizime may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Tenidap may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>Cefsulodin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Bendazac may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>Cefetamet may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Pranoprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Propyphenazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Proglumetacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>Isepamicin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Ethenzamide may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Mofebutazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>Cefbuperazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Proquazone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Benorilate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>Cefozopran may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>Bekanamycin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>Cefpirome may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Pirprofen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>Cefazedone may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>Acemetacin may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>Ceftezole may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Imidazole salicylate may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>Adefovir may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>SC-236 may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>NS-398 may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>Inotersen may decrease the excretion rate of Ceftazidime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Ceftazidime may decrease the excretion rate of Pyrithione which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Ceftazidime may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Ceftazidime may decrease the excretion rate of Resorcinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Ceftazidime may decrease the excretion rate of Golodirsen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Ceftazidime may decrease the excretion rate of Capreomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Ceftazidime may decrease the excretion rate of Codeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Ceftazidime may decrease the excretion rate of Amitriptyline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Ceftazidime may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>Ceftazidime may decrease the excretion rate of Meperidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Ceftazidime may decrease the excretion rate of Imipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Ceftazidime may decrease the excretion rate of Vancomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>Ceftazidime may decrease the excretion rate of Cisplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Ceftazidime may decrease the excretion rate of Carbamazepine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Ceftazidime may decrease the excretion rate of Pemetrexed which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Ceftazidime may decrease the excretion rate of Warfarin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Ceftazidime may decrease the excretion rate of Fentanyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Ceftazidime may decrease the excretion rate of Emtricitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Ceftazidime may decrease the excretion rate of Quinidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Ceftazidime may decrease the excretion rate of Isotretinoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Ceftazidime may decrease the excretion rate of Procainamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Ceftazidime may decrease the excretion rate of Doxepin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Ceftazidime may decrease the excretion rate of Desipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Ceftazidime may decrease the excretion rate of Clomipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Ceftazidime may decrease the excretion rate of Lithium cation which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Ceftazidime may decrease the excretion rate of Dimetacrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Ceftazidime may decrease the excretion rate of Plazomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Ceftazidime may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Ceftazidime may decrease the excretion rate of Lithium citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Ceftazidime may decrease the excretion rate of Lithium succinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Ceftazidime may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Torasemide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Chlorthalidone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Spironolactone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cyclothiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Eplerenone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>Conivaptan may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Trichlormethiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Diazoxide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Polythiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Tienilic acid may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>Tolvaptan may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>Indisulam may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Efonidipine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Ertugliflozin may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Cicletanine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Ibopamine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cyclopenthiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Muzolimine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Xipamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Ceftazidime is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00155</drugbank-id>
      <name>Citrulline</name>
      <description>The excretion of Citrulline can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The excretion of Aminohippuric acid can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The excretion of Grepafloxacin can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The excretion of Zidovudine can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The excretion of Stavudine can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>The excretion of Fluorescein can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The excretion of Dinoprostone can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00943</drugbank-id>
      <name>Zalcitabine</name>
      <description>The excretion of Zalcitabine can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The excretion of Captopril can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The excretion of Tazobactam can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02527</drugbank-id>
      <name>Cyclic adenosine monophosphate</name>
      <description>The excretion of Cyclic adenosine monophosphate can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03553</drugbank-id>
      <name>Glutaric Acid</name>
      <description>The excretion of Glutaric Acid can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The excretion of Taurocholic acid can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08846</drugbank-id>
      <name>Ellagic acid</name>
      <description>The excretion of Ellagic acid can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The excretion of Silibinin can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12243</drugbank-id>
      <name>Edaravone</name>
      <description>The excretion of Edaravone can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The therapeutic efficacy of Anagrelide can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The therapeutic efficacy of Argatroban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The therapeutic efficacy of Ardeparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Iloprost can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Heparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The therapeutic efficacy of Ximelagatran can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The therapeutic efficacy of Defibrotide can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The therapeutic efficacy of Ancrod can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Beraprost can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Sulodexide can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The therapeutic efficacy of Semuloparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The therapeutic efficacy of Idraparinux can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The therapeutic efficacy of Cangrelor can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The therapeutic efficacy of Apixaban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The therapeutic efficacy of Otamixaban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The therapeutic efficacy of Amediplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The therapeutic efficacy of Danaparoid can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The therapeutic efficacy of Dalteparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Ferulic acid can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The therapeutic efficacy of Nadroparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The therapeutic efficacy of Triflusal can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The therapeutic efficacy of Ditazole can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The therapeutic efficacy of Bemiparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The therapeutic efficacy of Reviparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The therapeutic efficacy of Parnaparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The therapeutic efficacy of Certoparin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The therapeutic efficacy of Desirudin can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The therapeutic efficacy of Zinc citrate can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The therapeutic efficacy of Protein C can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The therapeutic efficacy of Letaxaban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The therapeutic efficacy of Darexaban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The therapeutic efficacy of Betrixaban can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The therapeutic efficacy of Monteplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The therapeutic efficacy of Gabexate can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The therapeutic efficacy of Protein S human can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The therapeutic efficacy of Brinase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The therapeutic efficacy of Melagatran can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The therapeutic efficacy of Saruplase can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The therapeutic efficacy of Edetate calcium disodium anhydrous can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The therapeutic efficacy of Edetate disodium anhydrous can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of adverse effects can be increased when Ceftazidime is combined with Disulfiram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>The risk or severity of adverse effects can be increased when Ceftazidime is combined with Polymyxin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Ceftazidime may decrease the excretion rate of Baclofen which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.73e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ceftazidime</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>546.576</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>546.099138468</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C22H22N6O7S2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ORFOPKXBNMVMKC-DWVKKRMSSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>191.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>143.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>51.06</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.26</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>396 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>103-113</value>
      <source>O'Callaghan, C.H., Livermore, D.G.H. and Newall, C.E.; British Patent 2,025,398; January 23,&#13;
1980; assigned to Glaxo Group Ltd.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.60</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8344</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>3508</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5481173</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506143</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06889</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D07654</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4587145</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50420259</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448861</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000433</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Ceftazidime</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL44354</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/ceftaz.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/ceftazidime.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="5">
      <id>BE0002393</id>
      <name>Peptidoglycan synthase FtsI</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0AD68" source="Swiss-Prot">
        <name>Peptidoglycan synthase FtsI</name>
        <general-function>Peptidoglycan glycosyltransferase activity</general-function>
        <specific-function>Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan from the lipid-linked precursors (PubMed:7030331). Required for localization of FtsN (PubMed:9282742).</specific-function>
        <gene-name>ftsI</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>19-39</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.1</theoretical-pi>
        <molecular-weight>63876.925</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K00137</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0AD68</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FTSI_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.129</synonym>
          <synonym>PBP-3</synonym>
          <synonym>pbpB</synonym>
          <synonym>Penicillin-binding protein 3</synonym>
          <synonym>Peptidoglycan glycosyltransferase 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011715|Peptidoglycan synthase FtsI
MKAAAKTQKPKRQEEHANFISWRFALLCGCILLALAFLLGRVAWLQVISPDMLVKEGDMR
SLRVQQVSTSRGMITDRSGRPLAVSVPVKAIWADPKEVHDAGGISVGDRWKALANALNIP
LDQLSARINANPKGRFIYLARQVNPDMADYIKKLKLPGIHLREESRRYYPSGEVTAHLIG
FTNVDSQGIEGVEKSFDKWLTGQPGERIVRKDRYGRVIEDISSTDSQAAHNLALSIDERL
QALVYRELNNAVAFNKAESGSAVLVDVNTGEVLAMANSPSYNPNNLSGTPKEAMRNRTIT
DVFEPGSTVKPMVVMTALQRGVVRENSVLNTIPYRINGHEIKDVARYSELTLTGVLQKSS
NVGVSKLALAMPSSALVDTYSRFGLGKATNLGLVGERSGLYPQKQRWSDIERATFSFGYG
LMVTPLQLARVYATIGSYGIYRPLSITKVDPPVPGERVFPESIVRTVVHMMESVALPGGG
GVKAAIKGYRIAIKTGTAKKVGPDGRYINKYIAYTAGVAPASQPRFALVVVINDPQAGKY
YGGAVSAPVFGAIMGGVLRTMNIEPDALTTGDKNEFVINQGEGTGGRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011716|Peptidoglycan synthase FtsI (ftsI)
ATGAAAGCAGCGGCGAAAACGCAGAAACCAAAACGTCAGGAAGAACATGCCAACTTTATC
AGTTGGCGTTTTGCGTTGTTATGCGGCTGTATTCTCCTGGCGCTGGCTTTTCTGCTCGGA
CGCGTAGCGTGGTTACAAGTTATCTCCCCGGATATGCTGGTGAAAGAGGGCGACATGCGT
TCTCTTCGCGTTCAGCAAGTTTCCACCTCCCGCGGCATGATTACTGACCGTTCTGGTCGC
CCGTTAGCGGTGAGCGTGCCGGTAAAAGCGATTTGGGCTGACCCGAAAGAAGTGCATGAC
GCTGGCGGTATCAGCGTCGGTGACCGCTGGAAGGCGCTGGCTAACGCGCTCAATATTCCG
CTGGATCAGCTTTCAGCCCGCATTAACGCCAACCCGAAAGGGCGCTTTATTTATCTGGCG
CGTCAGGTGAACCCTGACATGGCGGACTACATCAAAAAACTGAAACTGCCGGGGATTCAT
CTGCGTGAAGAGTCTCGCCGTTACTATCCGTCCGGCGAAGTGACTGCTCACCTCATCGGC
TTTACTAACGTCGATAGTCAAGGGATTGAGGGCGTTGAGAAGAGTTTCGATAAATGGCTT
ACCGGGCAGCCGGGTGAGCGCATTGTGCGTAAAGACCGCTATGGTCGCGTAATTGAAGAT
ATTTCTTCTACTGACAGCCAGGCAGCGCACAACCTGGCGCTGAGTATTGATGAACGCCTG
CAGGCGCTGGTTTATCGCGAACTGAACAACGCGGTGGCCTTTAACAAGGCTGAATCTGGT
AGCGCCGTGCTGGTGGATGTCAACACCGGTGAAGTGCTGGCGATGGCTAACAGCCCGTCA
TACAACCCTAACAATCTGAGCGGCACGCCGAAAGAGGCGATGCGTAACCGTACCATCACC
GACGTGTTTGAACCGGGCTCAACGGTTAAACCGATGGTGGTAATGACCGCGTTGCAACGT
GGCGTGGTGCGGGAAAACTCGGTACTCAATACCATTCCTTATCGAATTAACGGCCACGAA
ATCAAAGACGTGGCACGCTACAGCGAATTAACCCTGACCGGGGTATTACAGAAGTCGAGT
AACGTCGGTGTTTCCAAGCTGGCGTTAGCGATGCCGTCCTCAGCGTTAGTAGATACTTAC
TCACGTTTTGGACTGGGAAAAGCGACCAATTTGGGGTTGGTCGGAGAACGCAGTGGCTTA
TATCCTCAAAAACAACGGTGGTCTGACATAGAGAGGGCCACCTTCTCTTTCGGCTACGGG
CTAATGGTAACACCATTACAGTTAGCGCGAGTCTACGCAACTATCGGCAGCTACGGCATT
TATCGCCCACTGTCGATTACCAAAGTTGACCCCCCGGTTCCCGGTGAACGTGTCTTCCCG
GAATCCATTGTCCGCACTGTGGTGCATATGATGGAAAGCGTGGCGCTACCAGGCGGCGGC
GGCGTGAAGGCGGCGATTAAAGGCTATCGTATCGCCATTAAAACCGGTACCGCGAAAAAG
GTCGGGCCGGACGGTCGCTACATCAATAAATATATTGCTTATACCGCAGGCGTTGCGCCT
GCGAGTCAGCCGCGCTTCGCGCTGGTTGTTGTTATCAACGATCCGCAGGCGGGTAAATAC
TACGGCGGCGCCGTTTCCGCGCCGGTCTTTGGTGCCATCATGGGCGGCGTATTGCGTACC
ATGAACATCGAGCCGGATGCGCTGACAACGGGCGATAAAAATGAATTTGTGATTAATCAA
GGCGAGGGGACAGGTGGCAGATCGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03717</identifier>
            <name>PBP_dimer</name>
          </pfam>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell division site</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0004643</id>
      <name>Penicillin-binding protein 3</name>
      <organism>Streptococcus pneumoniae</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q75Y35" source="TrEMBL">
        <name>Penicillin-binding protein 3</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function/>
        <gene-name>pbp3</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi/>
        <molecular-weight>45209.84</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1313">Streptococcus pneumoniae</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q75Y35</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q75Y35_STREE</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Putative D-alanyl-D-alanine carboxypeptidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017497|Penicillin-binding protein 3
MKKIFLTLLTVSLLGGASTAVAQDFTIAAKHAIAVEANTGKILYEKDATQPVEIASITKL
ITVYLVYEALENGSITLSTPVDISDYPYQLTTNSEASNIPMEARNYTVEELLEATLVSSA
NSAAIALAEKIAGSEKDFVDMMRAKLLEWGIQDATVVNTTGLNNETLGDNIYPGSKKDEE
NKLSAYDVAIVARNLIKKYPQVLEITKKPSSTFAGMTITSTNYMLEGMPAYRGGFDGLKT
GTTDKAGESFVGTTVEKGMRVITVVLNADHQDNNPYARFTATSSLMDYISSTFTLRKIVQ
QGDAYQDSKTPVQDGKEDTVTAVAPEDIYLIERVGNQSSQSVQFTPDSKAIPAPLEAGTV
VGHLTYEDKDLIGQGYITTERPSFEMVADKKIEKAFFLKVWWNQFVRFVNEKL</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF07943</identifier>
            <name>PBP5_C</name>
          </pfam>
          <pfam>
            <identifier>PF00768</identifier>
            <name>Peptidase_S11</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000588</id>
      <name>Penicillin-binding protein 1A</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02918" source="Swiss-Prot">
        <name>Penicillin-binding protein 1A</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).</specific-function>
        <gene-name>mrcA</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>6-26</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.53</theoretical-pi>
        <molecular-weight>93635.545</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>581194</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02918</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPA_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PBP-1a</synonym>
          <synonym>ponA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001173|Penicillin-binding protein 1A
MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQ
YGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGAST
ITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAA
QVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQF
DQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQ
QAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQ
QATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLA
QVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGL
TLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDY
AAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQG
GVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQA
LVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTT
NSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAY
MKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTI
IDNGEAQELF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020469|Penicillin-binding protein 1A (mrcA)
GTGAAGTTCGTAAAGTATTTTTTGATCCTTGCAGTCTGTTGCATTCTGCTGGGAGCAGGC
TCGATTTATGGCCTATACCGCTACATCGAGCCACAACTGCCGGATGTGGCGACATTAAAA
GATGTTCGCCTGCAAATTCCGATGCAGATTTACAGCGCCGATGGCGAGCTGATTGCTCAA
TACGGTGAGAAACGTCGTATTCCGGTTACGTTGGATCAAATCCCACCGGAGATGGTGAAA
GCCTTTATCGCGACAGAAGACAGCCGCTTCTACGAGCATCACGGCGTTGACCCGGTGGGG
ATCTTCCGTGCAGCAAGCGTGGCGCTGTTCTCCGGTCACGCGTCACAAGGGGCAAGTACC
ATTACCCAGCAGCTGGCGAGAAACTTCTTCCTCAGTCCAGAACGCACGCTGATGCGTAAG
ATTAAGGAAGTCTTCCTCGCGATTCGCATTGAACAGCTGCTGACGAAAGACGAGATCCTC
GAGCTTTATCTGAACAAGATTTACCTTGGTTACCGCGCCTATGGTGTCGGTGCTGCGGCA
CAAGTCTATTTCGGAAAAACGGTCGACCAACTGACGCTGAACGAAATGGCGGTGATAGCC
GGGCTGCCGAAAGCGCCTTCCACCTTCAACCCGCTCTACTCGATGGATCGTGCCGTCGCG
CGGCGTAACGTCGTGCTGTCGCGGATGCTGGATGAAGGGTATATCACCCAACAACAGTTC
GATCAGACACGCACTGAGGCGATTAACGCTAACTATCACGCGCCGGAGATTGCTTTCTCT
GCGCCGTACCTGAGCGAAATGGTGCGCCAGGAGATGTATAACCGTTATGGCGAAAGTGCC
TATGAAGACGGTTATCGCATTTACACCACCATCACCCGCAAAGTGCAGCAGGCCGCGCAG
CAGGCGGTACGTAATAACGTGCTGGACTACGACATGCGCCACGGCTATCGCGGCCCGGCA
AATGTGCTGTGGAAAGTGGGCGAGTCGGCGTGGGATAACAACAAGATTACCGATACGCTG
AAGGCGCTGCCAACCTATGGTCCGCTGCTGCCTGCCGCAGTCACCAGCGCCAATCCTCAG
CAAGCGACGGCGATGCTGGCGGACGGGTCGACCGTCGCATTGAGTATGGAAGGCGTTCGC
TGGGCGCGTCCTTACCGTTCGGATACTCAGCAAGGACCGACGCCGCGTAAAGTGACCGAT
GTTCTGCAAACGGGTCAGCAAATCTGGGTTCGTCAGGTTGGCGATGCATGGTGGCTGGCA
CAAGTGCCGGAAGTGAACTCGGCGCTGGTGTCGATCAATCCGCAAAACGGTGCCGTTATG
GCGCTGGTCGGTGGCTTTGATTTCAATCAGAGCAAGTTTAACCGCGCCACCCAGGCACTG
CGTCAGGTGGGTTCCAACATCAAACCGTTCCTCTACACCGCGGCGATGGATAAAGGTCTG
ACGCTGGCAAGTATGTTGAACGATGTGCCAATTTCTCGCTGGGATGCAAGTGCCGGTTCT
GACTGGCAGCCGAAGAACTCACCACCGCAGTATGCTGGTCCAATTCGCTTACGTCAGGGG
CTGGGTCAGTCGAAAAACGTGGTGATGGTACGCGCAATGCGGGCGATGGGCGTCGACTAC
GCTGCAGAATATCTGCAACGCTTCGGCTTCCCGGCACAAAACATTGTCCACACCGAATCG
CTGGCGCTGGGTTCAGCGTCCTTCACCCCAATGCAGGTGGCGCGCGGCTACGCGGTCATG
GCGAACGGCGGCTTCCTGGTGGACCCGTGGTTTATCAGCAAAATTGAAAACGATCAGGGC
GGCGTGATTTTCGAAGCGAAACCGAAAGTAGCCTGCCCGGAATGCGATATTCCGGTGATT
TACGGTGATACGCAGAAATCGAACGTGCTGGAAAATAACGATGTTGAAGATGTCGCTATC
TCCCGCGAGCAGCAGAATGTTTCTGTACCAATGCCGCAGCTGGAGCAGGCAAATCAGGCG
TTAGTGGCGAAGACTGGCGCGCAGGAGTACGCACCGCACGTCATCAACACTCCGCTGGCA
TTCCTGATTAAGAGTGCTTTGAACACCAATATCTTTGGTGAGCCAGGCTGGCAGGGTACT
GGCTGGCGTGCAGGTCGTGATTTGCAGCGTCGCGATATCGGCGGGAAAACCGGGACCACT
AACAGTTCGAAAGATGCGTGGTTCTCGGGTTACGGTCCGGGCGTTGTGACCTCGGTCTGG
ATTGGCTTTGATGATCACCGTCGTAATCTCGGTCATACAACGGCTTCCGGAGCGATTAAA
GATCAGATCTCAGGTTACGAAGGCGGTGCCAAGAGTGCCCAGCCTGCATGGGACGCTTAT
ATGAAAGCCGTTCTTGAAGGTGTGCCGGAGCAGCCGCTGACGCCGCCACCGGGTATTGTG
ACGGTGAATATCGATCGCAGCACCGGGCAGTTAGCTAATGGTGGCAACAGCCGCGAAGAG
TATTTCATCGAAGGTACGCAGCCGACACAACAGGCAGTGCACGAGGTGGGAACGACCATT
ATCGATAATGGCGAGGCACAGGAATTGTTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
          <pfam>
            <identifier>PF17092</identifier>
            <name>PCB_OB</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0004290</id>
      <name>Penicillin-binding protein 1A</name>
      <organism>Streptococcus pneumoniae (strain ATCC BAA-255 / R6)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q8DR59" source="Swiss-Prot">
        <name>Penicillin-binding protein 1A</name>
        <general-function>Penicillin binding</general-function>
        <specific-function>Cell wall formation.</specific-function>
        <gene-name>pbpA</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.29</theoretical-pi>
        <molecular-weight>79700.9</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="171101">Streptococcus pneumoniae (strain ATCC BAA-255 / R6)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M90527</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>153767</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8DR59</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPA_STRR6</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>exp2</synonym>
          <synonym>Exported protein 2</synonym>
          <synonym>PBP-1A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012992|Penicillin-binding protein 1A
MNKPTILRLIKYLSISFLSLVIAAIVLGGGVFFYYVSKAPSLSESKLVATTSSKIYDNKN
QLIADLGSERRVNAQANDIPTDLVKAIVSIEDHRFFDHRGIDTIRILGAFLRNLQSNSLQ
GGSALTQQLIKLTYFSTSTSDQTISRKAQEAWLAIQLEQKATKQEILTYYINKVYMSNGN
YGMQTAAQNYYGKDLNNLSLPQLALLAGMPQAPNQYDPYSHPEAAQDRRNLVLSEMKNQG
YISAEQYEKAVNTPITDGLQSLKSASNYPAYMDNYLKEVINQVEEETGYNLLTTGMDVYT
NVDQEAQKHLWDIYNTDEYVAYPDDELQVASTIVDVSNGKVIAQLGARHQSSNVSFGINQ
AVETNRDWGSTMKPITDYAPALEYGVYESTATIVHDEPYNYPGTNTPVYNWDRGYFGNIT
LQYALQQSRNVPAVETLNKVGLNRAKTFLNGLGIDYPSIHYSNAISSNTTESDKKYGASS
EKMAAAYAAFANGGTYYKPMYIHKVVFSDGSEKEFSNVGTRAMKETTAYMMTDMMKTVLS
YGTGRNAYLAWLPQAGKTGTSNYTDEEIENHIKTSQFVAPDELFAGYTRKYSMAVWTGYS
NRLTPLVGNGLTVAAKVYRSMMTYLSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWSSPA
PQQPPSTESSSSSSDSSTSQSSSTTPSTNNSTTTNPNNNTQQSNTTPDQQNQNPQPAQP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012993|Penicillin-binding protein 1A (pbpA)
ATGAACAAACCAACGATTCTGCGCCTAATCAAGTATCTGAGCATTAGCTTCTTAAGCTTG
GTTATCGCAGCCATTGTCTTAGGCGGAGGAGTTTTTTTCTACTACGTTAGCAAGGCTCCT
AGCCTATCCGAGAGTAAACTAGTTGCAACAACTTCTAGTAAAATCTACGACAATAAAAAT
CAACTCATTGCTGACTTGGGTTCTGAACGCCGCGTCAATGCCCAAGCTAATGATATTCCC
ACAGATTTGGTTAAGGCAATCGTTTCTATCGAAGACCATCGCTTCTTCGACCACAGGGGG
ATTGATACCATCCGTATCCTGGGAGCTTTCTTGCGCAATCTGCAAAGCAATTCCCTCCAA
GGTGGATCAGCTCTCACTCAACAGTTGATTAAGTTGACTTACTTTTCAACTTCGACTTCC
GACCAGACTATTTCTCGTAAGGCTCAGGAAGCTTGGTTAGCGATTCAGTTAGAACAAAAA
GCAACCAAGCAAGAAATCTTGACCTACTATATAAATAAGGTCTACATGTCTAATGGGAAC
TATGGAATGCAGACAGCAGCTCAAAACTACTATGGTAAAGACCTCAATAATTTAAGTTTA
CCTCAGTTAGCCTTGCTGGCTGGAATGCCTCAGGCACCAAACCAATATGACCCCTATTCA
CATCCAGAAGCAGCCCAAGACCGCCGAAACTTGGTCTTATCTGAAATGAAAAATCAAGGC
TACATCTCTGCTGAACAGTATGAGAAAGCAGTCAATACACCAATTACTGATGGGCTACAA
AGTCTCAAATCAGCAAGTAATTACCCTGCTTACATGGATAATTACCTCAAGGAAGTCATC
AATCAAGTTGAAGAAGAAACAGGCTATAACCTACTCACAACTGGGATGGATGTCTACACA
AATGTAGACCAAGAAGCTCAAAAACATCTGTGGGATATTTACAATACAGACGAATACGTT
GCCTATCCAGACGATGAATTGCAAGTCGCTTCTACCATTGTTGATGTTTCTAACGGTAAA
GTCATTGCCCAGCTAGGAGCACGCCATCAGTCAAGTAATGTTTCCTTCGGAATTAACCAA
GCAGTAGAAACAAACCGCGACTGGGGATCAACTATGAAACCGATCACAGACTATGCTCCT
GCCTTGGAGTACGGTGTCTACGAGTCAACTGCCACTATCGTTCACGATGAGCCCTATAAC
TACCCTGGGACAAATACCCCTGTTTATAACTGGGATAGGGGCTACTTTGGCAACATCACC
TTGCAATACGCCCTGCAACAATCGCGAAACGTCCCAGCCGTGGAAACTCTAAACAAGGTC
GGACTCAACCGCGCCAAGACTTTCCTAAATGGTCTCGGAATCGACTACCCAAGTATTCAC
TACTCAAATGCCATTTCAAGTAACACAACCGAATCAGACAAAAAATATGGAGCAAGTAGT
GAAAAGATGGCTGCTGCTTACGCTGCCTTTGCAAATGGTGGAACTTACTATAAACCAATG
TATATCCATAAAGTCGTCTTTAGTGATGGGAGTGAAAAAGAGTTCTCTAATGTCGGAACT
CGTGCCATGAAAGAAACGACAGCCTATATGATGACCGACATGATGAAAACAGTCTTGAGT
TATGGAACTGGACGAAATGCCTATCTTGCTTGGCTCCCTCAGGCTGGTAAAACAGGAACC
TCTAACTATACAGACGAGGAAATTGAAAACCACATCAAGACCTCTCAATTTGTAGCACCT
GATGAACTATTTGCTGGCTATACGCGTAAATATTCAATGGCTGTATGGACAGGCTATTCT
AACCGTCTGACACCACTTGTAGGCAATGGCCTTACGGTCGCTGCCAAAGTTTACCGCTCT
ATGATGACCTACCTGTCTGAAGGAAGCAATCCAGAGGATTGGAATATACCAGAGGGGCTC
TACAGAAATGGAGAATTCGTATTTAAAAATGGTGCTCGTTCTACGTGGAGCTCACCTGCT
CCACAACAACCCCCATCAACTGAAAGTTCAAGCTCATCATCAGATAGTTCAACTTCACAG
TCTAGCTCAACCACTCCAAGCACAAATAATAGTACGACTACCAATCCTAACAATAATACG
CAACAATCAAATACAACCCCTGATCAACAAAATCAGAATCCTCAACCAGCACAACCATAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0000488</id>
      <name>Penicillin-binding protein 1B</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02919" source="Swiss-Prot">
        <name>Penicillin-binding protein 1B</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).</specific-function>
        <gene-name>mrcB</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>64-87</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.46</theoretical-pi>
        <molecular-weight>94291.875</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02163</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>42468</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02919</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPB_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Murein polymerase</synonym>
          <synonym>PBP-1b</synonym>
          <synonym>pbpF</synonym>
          <synonym>ponB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000974|Penicillin-binding protein 1B
MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPR
GKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTIS
KNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHL
ATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEH
DGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDAR
YSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIY
NPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQ
ELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRF
SGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIAL
RQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPK
DQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAER
AVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTI
TWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGM
RILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDM
FGSN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018961|Penicillin-binding protein 1B (mrcB)
ATGGCCGGGAATGACCGCGAGCCAATTGGACGCAAAGGGAAACCGACGCGTCCGGTCAAA
CAAAAGGTAAGCCGTCGTCGTTACGAAGATGACGATGATTACGACGATTATGATGACTAT
GAGGATGAAGAACCGATGCCGCGCAAAGGTAAGGGCAAAGGCAAAGGGCGTAAGCCTCGT
GGCAAACGCGGCTGGCTATGGCTACTGCTAAAACTGGCTATCGTTTTTGCCGTGCTGATC
GCCATTTACGGCGTTTATCTCGATCAAAAAATTCGTAGCCGTATTGATGGCAAGGTCTGG
CAACTGCCTGCGGCAGTTTATGGCCGAATGGTCAATCTTGAGCCAGACATGACCATCAGC
AAGAACGAGATGGTGAAGCTGCTGGAGGCGACCCAGTATCGTCAGGTGTCGAAAATGACC
CGTCCTGGCGAATTTACCGTGCAGGCCAACAGCATTGAGATGATTCGCCGTCCGTTTGAT
TTCCCGGACAGTAAAGAAGGACAGGTGCGCGCGCGTCTGACCTTTGATGGCGATCATCTG
GCGACGATCGTCAATATGGAGAACAACCGTCAGTTCGGTTTCTTCCGTCTTGATCCGCGT
CTGATCACCATGATCTCTTCGCCAAACGGTGAGCAGCGTCTGTTTGTGCCGCGCAGTGGT
TTCCCGGATTTGCTGGTGGATACTTTGCTGGCGACAGAAGACCGTCATTTTTACGAGCAT
GATGGAATCAGTCTCTACTCAATCGGACGTGCGGTGCTGGCAAACCTGACCGCCGGACGC
ACGGTACAGGGTGCGAGTACGCTGACGCAACAGCTGGTGAAAAACCTGTTCCTCTCCAGC
GAGCGTTCTTACTGGCGTAAAGCGAACGAAGCTTACATGGCGCTGATCATGGACGCGCGT
TACAGCAAAGACCGTATTCTTGAGCTGTATATGAACGAGGTGTATCTCGGTCAGAGCGGC
GACAACGAAATCCGCGGCTTCCCGCTGGCAAGCTTGTATTACTTTGGTCGCCCGGTAGAA
GAGCTAAGCCTCGACCAGCAGGCGCTGTTAGTCGGTATGGTGAAAGGGGCGTCCATCTAC
AACCCGTGGCGTAACCCAAAACTGGCGCTGGAGCGACGTAATCTGGTGCTGCGTCTGCTG
CAACAGCAACAGATTATTGATCAAGAACTCTATGACATGTTGAGTGCCCGTCCGCTGGGG
GTTCAGCCGCGCGGTGGGGTGATCTCTCCTCAGCCAGCCTTTATGCAACTGGTGCGTCAG
GAGCTGCAGGCAAAACTGGGCGATAAGGTAAAAGATCTCTCCGGCGTGAAGATCTTCACT
ACCTTTGACTCGGTGGCCCAGGACGCGGCAGAAAAAGCCGCCGTGGAAGGCATTCCGGCA
CTGAAGAAACAGCGTAAGTTGAGCGATCTTGAAACTGCGATTGTGGTCGTCGACCGCTTT
AGTGGTGAAGTTCGTGCGATGGTCGGAGGTTCTGAGCCGCAGTTTGCGGGCTACAACCGT
GCGATGCAGGCGCGTCGTTCGATTGGTTCCCTTGCAAAACCAGCGACTTATCTGACGGCC
TTAAGCCAGCCGAAAATCTATCGTCTGAATACGTGGATTGCGGATGCGCCAATTGCGCTG
CGTCAGCCGAATGGCCAGGTCTGGTCACCGCAGAATGATGACCGTCGTTATAGCGAAAGC
GGCAGAGTGATGCTGGTGGATGCGTTGACCCGTTCGATGAACGTGCCGACGGTAAATCTG
GGGATGGCGCTGGGGCTGCCTGCGGTTACGGAGACCTGGATTAAACTGGGCGTACCGAAA
GATCAGTTGCATCCGGTTCCGGCAATGCTGCTGGGGGCGTTGAACTTAACGCCAATCGAA
GTGGCGCAGGCATTCCAGACCATCGCCAGCGGTGGTAACCGTGCACCGCTTTCTGCGCTG
CGTTCGGTAATCGCGGAAGATGGCAAAGTGCTGTATCAGAGCTTCCCGCAGGCGGAACGC
GCTGTTCCGGCGCAGGCGGCGTATCTGACACTATGGACCATGCAGCAGGTGGTACAACGC
GGTACGGGTCGTCAGCTTGGGGCGAAATACCCGAACCTGCATCTGGCAGGGAAAACAGGG
ACTACCAACAATAACGTAGATACCTGGTTTGCGGGCATTGACGGCAGCACGGTGACCATC
ACCTGGGTCGGCCGTGATAACAACCAGCCGACCAAACTGTATGGTGCCAGCGGGGCAATG
TCGATTTATCAGCGTTATCTGGCTAACCAGACGCCAACGCCGCTGAATCTTGTTCCGCCA
GAAGATATTGCAGATATGGGCGTGGACTACGACGGCAACTTTGTTTGCAGCGGTGGCATG
CGTATCTTGCCGGTCTGGACCAGCGATCCGCAATCGCTGTGCCAGCAGAGCGAGATGCAG
CAGCAGCCGTCAGGCAATCCGTTTGATCAGTCTTCTCAGCCGCAGCAACAGCCGCAACAG
CAACCTGCTCAGCAAGAGCAGAAAGACAGCGACGGTGTAGCCGGTTGGATCAAGGATATG
TTTGGTAGTAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
          <pfam>
            <identifier>PF14814</identifier>
            <name>UB2H</name>
          </pfam>
          <pfam>
            <identifier>PF14812</identifier>
            <name>PBP1_TM</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peptidoglycan-based cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0003687</id>
      <name>Penicillin-binding protein 1B</name>
      <organism>Pseudomonas aeruginosa</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9X6W0" source="TrEMBL">
        <name>Penicillin-binding protein 1B</name>
        <general-function>Peptidoglycan glycosyltransferase activity</general-function>
        <specific-function>Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).</specific-function>
        <gene-name>ponB</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions>23-45</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.57</theoretical-pi>
        <molecular-weight>85486.615</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="">Pseudomonas aeruginosa</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF147449</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4887211</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9X6W0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q9X6W0_PSEAI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>mrcB</synonym>
          <synonym>Murein polymerase</synonym>
          <synonym>PBP-1b</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022481|Penicillin-binding protein 1B
MTRPRSPRSRNSKARPAPGLNKWLSWALKLGLVGLVLLAGFAIYLDAVVQEKFSGRRWTI
PAKVYARPLELFNGLKLSREDFLRELDALGYRREPSVSGPGTVSVAASAVELNTRGFQFY
EGAEPAQRVRVRFNGNYVSGLSQANGKELAVARLEPLLIGGLYPAHHEDRILVKLDQVPT
YLIDTLVAVEDRDFWNHHGVSLKSVARAVWVNTTAGQLRQGGSTLTQQLVKNFFLSNERS
LSRKINEAMMAVLLELHYDKRDILESYLNEVFLGQDGQRAIHGFGLASQYFFSQPLAELK
LDQVALLVGMVKGPSYFNPRRYPDRALARRNLVLDVLAEQGVATQQEVDAAKLRPLGVTR
QGSMADSSYPAFLDLVKRQLRQDYRDEDLTEEGLRIFTSFDPILQEKAETSVNETLKRLS
GRKGVDQVEAAMVVTNPETGEIQALIGSRDPRFAGFNRALDAVRPIGSLIKPAVYLTALE
RPSKYTLTTWVQDEPFAVKGQDGQVWRPQNYDRRSHGTIFLYQGLANSYNLSTAKLGLDV
GVPNVLQTVARLGINRDWPAYPSMLLGAGSLSPMEVATMYQTIASGGFNTPLRGIRSVLT
ADGQPLKRYPFQVEQRFDSGAVYLVQNAMQRVMREGTGRSVYSQLPSSLTLAGKTGTSND
SRDSWFSGFGGDLQAVVWLGRDDNGKTPLTGATGALQVWASFMRKAHPQSLEMPMPENVV
MAWVDAQTGQGSAADCPNAVQMPYIRGSEPAQGPGCGSQNPAGEVMDWVRGWLN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0022482|Penicillin-binding protein 1B (ponB)
ATGACGCGTCCCCGATCCCCCCGTTCCCGTAACAGCAAAGCACGCCCGGCACCCGGCCTG
AACAAATGGCTCAGCTGGGCTCTCAAGCTCGGCCTCGTCGGCCTGGTGCTCCTCGCCGGC
TTCGCCATCTATCTCGATGCCGTGGTGCAGGAGAAATTCTCCGGCCGGCGCTGGACCATC
CCGGCGAAGGTCTATGCCCGCCCGCTGGAGCTGTTCAACGGCCTGAAGCTGAGCAGGGAA
GACTTCCTGCGCGAACTCGACGCCCTCGGCTACCGTCGCGAGCCCAGCGTGAGCGGCCCT
GGAACCGTATCGGTGGCGGCCAGCGCGGTCGAACTCAATACCCGTGGCTTCCAGTTCTAC
GAAGGCGCGGAACCGGCCCAGCGCGTGCGCGTGCGCTTCAACGGCAACTACGTCAGCGGG
CTGAGCCAGGCCAACGGCAAGGAACTGGCGGTGGCGCGCCTTGAGCCGCTGCTGATCGGC
GGCTTGTATCCGGCGCACCATGAGGATCGCATCCTGGTCAAGCTCGACCAGGTGCCGACC
TACCTGATCGACACCCTGGTCGCGGTCGAGGATCGCGACTTCTGGAACCACCATGGTGTG
TCGCTGAAATCCGTGGCGCGGGCGGTGTGGGTCAACACCACGGCCGGCCAGTTGCGCCAG
GGCGGCAGCACCCTGACCCAGCAGTTGGTGAAGAACTTCTTCCTGAGCAATGAGCGCAGC
CTGAGCCGCAAGATCAACGAAGCGATGATGGCGGTGCTGCTGGAACTGCACTACGACAAG
CGCGACATCCTCGAGTCCTATCTCAACGAGGTGTTCCTCGGCCAGGATGGGCAACGAGCG
ATCCATGGCTTCGGCCTGGCCAGCCAGTATTTCTTCAGCCAGCCGTTGGCCGAGCTCAAG
CTCGACCAGGTGGCGCTGCTGGTCGGCATGGTCAAGGGGCCGTCCTACTTCAACCCGCGG
CGTTACCCGGATCGTGCGCTGGCGCGGCGCAACCTGGTGCTCGACGTGCTCGCCGAGCAG
GGCGTGGCGACCCAGCAGGAAGTCGACGCCGCCAAGCTGCGCCCGCTCGGCGTGACCCGG
CAGGGCAGCATGGCCGACAGCTCCTATCCGGCCTTCCTCGACCTGGTCAAGCGCCAGTTG
CGCCAGGACTACCGCGACGAGGACCTGACTGAGGAAGGGCTGCGCATCTTCACCAGCTTC
GATCCGATCCTGCAGGAGAAGGCCGAGACCTCCGTCAACGAAACGCTCAAGCGTCTCAGT
GGGCGCAAGGGGGTCGACCAGGTCGAGGCGGCGATGGTCGTGACCAATCCGGAAACCGGT
GAGATCCAGGCCCTGATCGGCAGTCGCGACCCGCGCTTCGCCGGCTTCAACCGGGCCCTG
GACGCGGTGCGGCCGATCGGTTCGCTGATCAAGCCGGCGGTCTACCTGACCGCTCTCGAG
CGGCCGAGCAAGTACACCCTGACCACCTGGGTACAGGACGAGCCCTTCGCGGTGAAAGGC
CAGGACGGCCAGGTCTGGCGACCGCAGAACTACGACCGGCGCTCGCATGGCACGATCTTC
CTGTACCAGGGCCTGGCAAACTCCTACAACCTGTCCACCGCCAAGCTCGGCCTCGACGTC
GGTGTGCCCAACGTGCTGCAGACCGTCGCCCGGCTGGGTATCAACCGTGACTGGCCGGCC
TATCCGTCGATGCTGCTGGGCGCCGGTTCGCTCAGTCCGATGGAGGTCGCCACCATGTAC
CAGACCATCGCCAGCGGCGGCTTCAACACGCCGTTGCGGGGGATCCGCAGCGTCCTCACT
GCCGACGGCCAGCCGCTCAAGCGCTATCCGTTCCAGGTCGAACAGCGCTTCGACTCGGGC
GCCGTCTACCTGGTGCAGAACGCCATGCAGCGGGTCATGCGCGAAGGCACCGGGCGTTCG
GTGTACAGTCAATTGCCGTCGTCGCTGACCCTCGCCGGCAAGACCGGCACCAGCAACGAC
TCGCGCGATAGCTGGTTCTCCGGTTTCGGCGGCGACCTCCAGGCTGTGGTCTGGCTCGGT
CGCGACGACAACGGCAAGACGCCGCTTACCGGCGCCACCGGTGCCTTGCAGGTGTGGGCC
AGCTTCATGCGCAAGGCGCATCCGCAATCGCTGGAAATGCCGATGCCGGAGAACGTGGTG
ATGGCCTGGGTCGACGCGCAGACCGGGCAGGGCTCGGCGGCGGATTGCCCGAATGCCGTA
CAGATGCCCTATATTCGTGGCAGCGAGCCCGCCCAGGGCCCAGGCTGCGGGAGCCAGAAC
CCCGCCGGCGAGGTGATGGACTGGGTACGTGGCTGGCTGAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
          <pfam>
            <identifier>PF14814</identifier>
            <name>UB2H</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peptidoglycan-based cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="11">
      <id>BE0004648</id>
      <name>Penicillin-binding protein 2</name>
      <organism>Pseudomonas aeruginosa</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9X6V3" source="TrEMBL">
        <name>Penicillin-binding protein 2</name>
        <general-function>Penicillin binding</general-function>
        <specific-function/>
        <gene-name>pbpA</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions>21-40</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>72212.855</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="">Pseudomonas aeruginosa</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9X6V3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q9X6V3_PSEAI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>penA</synonym>
          <synonym>Sporulation-specific penicillin-binding protein</synonym>
          <synonym>spoVD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022345|Penicillin-binding protein 2
MPQPIHLKDHEKDARLVRRRVIVGAVAVVLLTLVLVARMYHLQVTQYEYHSTLSENNRVH
VQPIPPTRGIIFDRNGVIIADNRPSFSLTITRERTEDLQKTLDTLVEILGLTEDDRAIFE
KRMKQGRRPFEPVPIMFELNEEQIARIAVNQFRLPGVDVATQFVRHYPLKEHFAHSVGYV
GRINEQELKNLDPINYSGTHHIGKTGIERFYESELHGTVGYEEVETNARGRVLRVLKRTD
PIPGKDIVLSIDSRLQEAAENALAGRRGAIVAIQPSTGDVLAMVSQPSYDPNLFVTGISF
KAYAELRDSIDRPLYNRVLRGLYPPGSTVKPAVALAGLDAGVVTPTSRVFDPGYYQLPNY
DHKYRNWNRYGDGWVSLESAIYRSNDTYFYDLAHKLGIDRLHAFMSRFGFGQKVALDMFG
EADGLMPSREWKRKTRRQVWYPGETLILGIGQGYMQATPIQLAQMTALLANKGHWIRPHL
AKTIDGQPPVDPDPMPDIVLRDPANWDRVDYGMQQVVHGARGTARKVGATSAYLIAGKSG
TAQVVAIKQNERYDRSKLLERHRDHALFVGFAPANNPQIAVAVMVENGESGSGVAAPVVK
QVMDAWLLDEHGKLKAEYAEPVAPLAAAVAKPEPTAAEPEAPALEQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0022346|Penicillin-binding protein 2 (pbpA)
ATGCCGCAGCCGATCCACCTGAAAGACCACGAGAAAGACGCCCGCCTGGTGCGTCGGCGC
GTCATCGTCGGGGCGGTGGCGGTGGTCTTGCTGACCCTGGTGCTGGTGGCGCGCATGTAC
CACCTGCAGGTGACCCAGTACGAGTACCATTCGACGCTGTCGGAGAACAACCGGGTCCAT
GTGCAGCCGATCCCGCCGACCCGCGGGATCATCTTCGACCGCAACGGCGTGATCATCGCC
GACAACCGGCCGAGCTTCAGCCTGACCATCACCCGCGAACGCACCGAGGACCTGCAGAAG
ACCCTCGACACGCTGGTGGAGATCCTCGGCCTGACCGAGGACGACCGGGCCATCTTCGAG
AAGCGCATGAAGCAGGGGCGGCGTCCGTTCGAGCCGGTTCCCATCATGTTCGAACTCAAC
GAGGAACAGATCGCCCGCATCGCGGTGAACCAGTTCCGCCTGCCGGGCGTCGACGTGGCG
ACCCAGTTCGTCCGCCACTACCCGCTGAAGGAGCACTTCGCCCATTCGGTCGGGTACGTC
GGGCGGATCAACGAGCAGGAACTGAAGAACCTCGACCCGATTAACTACAGCGGCACCCAC
CATATCGGCAAGACCGGCATCGAGCGCTTCTACGAGAGCGAGTTGCACGGCACGGTTGGC
TACGAGGAAGTCGAGACCAACGCCCGCGGGCGGGTGCTGCGGGTGCTCAAGCGCACCGAC
CCGATTCCCGGCAAGGACATCGTCCTGAGCATCGACAGCCGCCTGCAGGAGGCCGCCGAG
AACGCCCTGGCCGGGCGGCGGGGCGCCATCGTGGCGATCCAGCCGTCCACCGGCGACGTG
CTGGCGATGGTCAGCCAGCCGAGCTACGACCCCAACCTGTTCGTCACCGGCATCAGCTTC
AAGGCCTATGCCGAGCTGCGTGACTCCATCGACCGGCCGCTGTACAACCGCGTCCTGCGC
GGGCTCTATCCGCCGGGCTCGACGGTGAAGCCGGCGGTGGCGCTGGCCGGCCTCGACGCC
GGGGTGGTCACGCCGACCTCGCGGGTCTTCGACCCCGGCTACTACCAGTTGCCCAACTAC
GACCACAAGTACCGTAACTGGAACCGCTACGGCGATGGCTGGGTGAGCCTGGAGTCGGCG
ATCTACCGGTCCAACGACACCTATTTCTACGACCTCGCGCACAAGCTGGGGATCGACCGC
CTGCACGCCTTCATGAGCCGCTTCGGCTTCGGCCAGAAAGTCGCCCTGGACATGTTCGGC
GAAGCCGACGGGCTGATGCCCTCGCGCGAATGGAAGCGCAAGACCCGCCGCCAGGTCTGG
TACCCGGGCGAGACCCTGATCCTCGGCATCGGCCAGGGCTACATGCAGGCGACGCCGATC
CAACTGGCGCAGATGACCGCGCTGCTGGCCAACAAGGGCCACTGGATCCGCCCGCACCTG
GCCAAGACCATCGACGGCCAGCCGCCGGTCGACCCCGACCCGATGCCCGACATCGTGCTG
CGCGACCCGGCCAACTGGGACCGCGTCGACTACGGCATGCAGCAGGTGGTGCATGGCGCC
CGCGGCACGGCGCGCAAGGTCGGCGCCACCTCGGCCTACCTGATCGCCGGCAAGAGCGGT
ACCGCCCAGGTGGTGGCGATCAAGCAGAACGAGCGCTACGACCGCTCCAAGCTGCTCGAG
CGGCACCGCGACCACGCCCTGTTCGTCGGCTTCGCGCCGGCCAACAACCCGCAGATCGCG
GTGGCGGTGATGGTGGAGAACGGCGAGTCCGGCTCCGGCGTCGCCGCCCCGGTGGTCAAG
CAGGTGATGGACGCCTGGCTGCTCGACGAGCACGGCAAGCTCAAGGCCGAATACGCGGAA
CCCGTCGCGCCGCTCGCGGCGGCGGTGGCCAAGCCCGAACCCACGGCAGCCGAGCCGGAG
GCGCCCGCCCTTGAACAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03717</identifier>
            <name>PBP_dimer</name>
          </pfam>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0003579</id>
      <name>Penicillin-binding protein 2</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0AD65" source="Swiss-Prot">
        <name>Penicillin-binding protein 2</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross-linked peptidoglycan from lipid intermediates.</specific-function>
        <gene-name>mrdA</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>22-42</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.16</theoretical-pi>
        <molecular-weight>70856.1</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04516</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>42314</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0AD65</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBP2_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PBP-2</synonym>
          <synonym>pbpA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017144|Penicillin-binding protein 2
MKLQNSFRDYTAESALFVRRALVAFLGILLLTGVLIANLYNLQIVRFTDYQTRSNENRIK
LVPIAPSRGIIYDRNGIPLALNRTIYQIEMMPEKVDNVQQTLDALRSVVDLTDDDIAAFR
KERARSHRFTSIPVKTNLTEVQVARFAVNQYRFPGVEVKGYKRRYYPYGSALTHVIGYVS
KINDKDVERLNNDGKLANYAATHDIGKLGIERYYEDVLHGQTGYEEVEVNNRGRVIRQLK
EVPPQAGHDIYLTLDLKLQQYIETLLAGSRAAVVVTDPRTGGVLALVSTPSYDPNLFVDG
ISSKDYSALLNDPNTPLVNRATQGVYPPASTVKPYVAVSALSAGVITRNTTLFDPGWWQL
PGSEKRYRDWKKWGHGRLNVTRSLEESADTFFYQVAYDMGIDRLSEWMGKFGYGHYTGID
LAEERSGNMPTREWKQKRFKKPWYQGDTIPVGIGQGYWTATPIQMSKALMILINDGIVKV
PHLLMSTAEDGKQVPWVQPHEPPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYK
IAAKSGTAQVFGLKANETYNAHKIAERLRDHKLMTAFAPYNNPQVAVAMILENGGAGPAV
GTLMRQILDHIMLGDNNTDLPAENPAVAAAEDH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017145|Penicillin-binding protein 2 (mrdA)
ATGAAACTACAGAACTCTTTTCGCGACTATACGGCAGAGTCCGCGCTGTTTGTGCGCCGG
GCGCTGGTCGCCTTTTTGGGGATTTTGCTGCTGACCGGCGTGCTTATCGCCAACCTGTAT
AATCTGCAAATTGTTCGCTTTACCGACTACCAGACCCGCTCTAATGAAAACCGCATTAAG
CTGGTGCCTATCGCGCCCAGCCGCGGCATTATCTACGATCGTAACGGTATCCCTCTGGCC
CTCAACCGCACTATCTACCAGATAGAAATGATGCCGGAGAAAGTCGATAACGTGCAGCAA
ACGCTGGACGCTTTGCGCAGCGTGGTAGATCTGACCGATGACGATATTGCTGCATTCCGA
AAAGAGCGCGCACGTTCACACCGTTTCACCTCTATTCCGGTGAAAACTAACCTGACCGAA
GTACAAGTAGCTCGCTTTGCCGTCAATCAGTACCGTTTTCCGGGTGTCGAAGTTAAAGGC
TATAAACGTCGTTACTATCCTTACGGTTCGGCGTTGACCCACGTCATCGGCTATGTGTCG
AAAATCAACGATAAAGACGTCGAACGCCTGAATAATGACGGCAAACTGGCCAACTATGCG
GCAACGCATGATATCGGTAAGCTGGGCATTGAGCGTTACTATGAAGATGTGCTGCACGGT
CAGACCGGTTATGAAGAGGTTGAAGTTAACAACCGTGGGCGTGTTATTCGCCAGTTAAAA
GAAGTACCACCGCAAGCCGGACACGATATTTACCTGACGCTGGATCTCAAACTCCAGCAA
TATATTGAAACGCTGCTGGCGGGTAGCCGCGCAGCTGTGGTAGTCACCGATCCGCGTACA
GGTGGGGTGCTGGCGCTGGTTTCCACGCCTAGTTATGACCCAAACTTGTTTGTTGACGGT
ATCTCCAGCAAAGATTATTCCGCCTTGTTGAACGATCCGAATACACCGCTGGTGAACCGC
GCCACACAGGGGGTTTATCCTCCCGCGTCTACAGTTAAACCCTATGTGGCGGTTTCGGCA
TTGAGCGCCGGGGTGATCACGCGCAATACGACGCTGTTTGACCCAGGCTGGTGGCAACTG
CCAGGTTCGGAAAAACGTTATCGTGACTGGAAAAAATGGGGCCACGGGCGTCTGAATGTC
ACAAGATCGCTGGAAGAATCTGCGGATACCTTCTTCTATCAGGTGGCCTACGATATGGGG
ATCGATCGCCTCTCCGAATGGATGGGTAAATTCGGTTATGGTCATTACACCGGTATCGAC
CTGGCGGAAGAACGTTCCGGCAACATGCCTACCCGCGAATGGAAACAGAAACGCTTTAAA
AAACCGTGGTATCAGGGTGACACCATTCCGGTTGGTATCGGTCAGGGTTACTGGACAGCG
ACCCCAATCCAGATGAGTAAGGCACTGATGATCCTGATTAATGACGGTATCGTGAAGGTT
CCTCATTTGCTGATGAGCACCGCCGAAGACGGCAAACAGGTGCCATGGGTACAGCCGCAT
GAACCGCCCGTCGGCGATATTCATTCCGGTTACTGGGAGCTGGCGAAAGACGGTATGTAC
GGTGTTGCTAACCGCCCTAACGGTACGGCGCATAAATACTTTGCTAGCGCACCGTACAAA
ATTGCGGCGAAATCCGGTACCGCTCAGGTCTTCGGTCTGAAAGCGAACGAAACCTATAAT
GCGCACAAAATTGCCGAGCGTTTACGTGACCACAAACTGATGACCGCCTTTGCGCCATAC
AACAATCCGCAAGTGGCTGTCGCCATGATTCTGGAGAACGGTGGTGCGGGTCCGGCGGTT
GGTACACTGATGCGCCAGATCCTCGACCACATTATGCTGGGTGATAACAACACCGATCTG
CCTGCGGAAAATCCAGCGGTTGCCGCAGCGGAGGACCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03717</identifier>
            <name>PBP_dimer</name>
          </pfam>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan L,D-transpeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="13">
      <id>BE0004649</id>
      <name>D-alanyl-D-alanine endopeptidase</name>
      <organism>Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16721</ref-id>
            <pubmed-id>6413485</pubmed-id>
            <citation>Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P72161" source="Swiss-Prot">
        <name>D-alanyl-D-alanine endopeptidase</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation.</specific-function>
        <gene-name>pbpG</gene-name>
        <locus/>
        <cellular-location>Periplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi/>
        <molecular-weight>34046.065</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="208964">Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P72161</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBP5_PSEAE</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.-</synonym>
          <synonym>DD-endopeptidase</synonym>
          <synonym>PBP-5</synonym>
          <synonym>Penicillin-binding protein 5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013238|D-alanyl-D-alanine endopeptidase
MRNRLLSLVTLFLSLSVATAVSASPPPKAGLPLQQELASGSALVTDQNTGKVLYSRNPDL
VVPIASITKLMTAMVVLDSKLPLDEVLPIAISETSEMRGVFSRVRVGSQISRRDMLLLAL
MSSENRAAASLAQNYPGGKNAFVKAMNAKAHALGMKNTRYVEPTGLSLHNVSTARDLTRL
LVASRQYPLLSQWSTTPEKTVAFRHPNYTLGFRNTNHLINNKTWNIQLTKTGFTNEAGHC
LVMRTTINRSPVNLVVLDAFGKYTHFADATRLRRWLETGQVTAIPAAAKAYRLQRDRERG
LGQPVAQAVR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013239|D-alanyl-D-alanine endopeptidase (pbpG)
GTGAGAAACCGTCTCCTGTCACTGGTCACCCTGTTCCTGTCCCTCAGCGTTGCCACCGCG
GTATCCGCCTCCCCGCCGCCCAAGGCCGGGCTGCCGCTGCAACAGGAGCTGGCGTCGGGC
AGCGCGCTGGTTACCGACCAGAACACCGGCAAGGTACTCTACTCGCGCAACCCCGACCTG
GTGGTGCCGATCGCCTCAATCACCAAGCTGATGACCGCCATGGTCGTGCTCGACTCGAAA
CTGCCGCTGGACGAGGTACTGCCGATCGCCATCAGCGAGACCAGCGAAATGCGCGGGGTG
TTTTCCCGGGTGCGGGTCGGCAGCCAGATCAGCCGCCGGGACATGCTCCTGCTCGCCCTG
ATGTCCTCGGAGAACCGCGCCGCCGCCAGCCTCGCGCAGAACTATCCGGGCGGCAAGAAC
GCCTTCGTCAAGGCGATGAACGCCAAGGCCCACGCCCTGGGAATGAAGAACACCCGCTAC
GTCGAGCCGACCGGGCTGTCGCTGCACAACGTCTCCACCGCTCGCGACCTCACCCGCCTG
CTGGTGGCCAGCCGGCAATATCCGCTGCTCAGTCAGTGGAGCACCACTCCGGAGAAGACC
GTGGCCTTCCGCCACCCCAACTACACCCTGGGCTTCCGCAACACCAACCACCTGATCAAC
AACAAGACCTGGAACATCCAGTTGACCAAGACCGGCTTCACCAACGAGGCAGGCCACTGC
CTGGTGATGCGCACCACGATCAACCGCAGCCCGGTCAATCTGGTGGTGCTGGACGCCTTC
GGCAAGTACACCCACTTCGCCGACGCCACGCGCCTGCGACGCTGGCTGGAAACCGGCCAG
GTCACTGCGATCCCGGCCGCGGCCAAGGCCTATCGCCTGCAACGCGACCGCGAGCGCGGC
CTCGGCCAGCCGGTGGCCCAGGCCGTACGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00768</identifier>
            <name>Peptidase_S11</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>periplasmic space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0000106</id>
      <name>Solute carrier family 22 member 5</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16110</ref-id>
            <pubmed-id>10636865</pubmed-id>
            <citation>Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O76082" source="Swiss-Prot">
        <name>Solute carrier family 22 member 5</name>
        <general-function>Symporter activity</general-function>
        <specific-function>Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.</specific-function>
        <gene-name>SLC22A5</gene-name>
        <locus>5q31</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>21-41
143-163
173-193
198-218
233-253
258-278
342-362
374-394
407-427
431-451
463-483
489-509</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.04</theoretical-pi>
        <molecular-weight>62751.08</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10969</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC22A5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3273741</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O76082</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>High-affinity sodium-dependent carnitine cotransporter</synonym>
          <synonym>OCTN2</synonym>
          <synonym>Organic cation/carnitine transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000212|Solute carrier family 22 member 5
MRDYDEVTAFLGEWGPFQRLIFFLLSASIIPNGFTGLSSVFLIATPEHRCRVPDAANLSS
AWRNHTVPLRLRDGREVPHSCRRYRLATIANFSALGLEPGRDVDLGQLEQESCLDGWEFS
QDVYLSTIVTEWNLVCEDDWKAPLTISLFFVGVLLGSFISGQLSDRFGRKNVLFVTMGMQ
TGFSFLQIFSKNFEMFVVLFVLVGMGQISNYVAAFVLGTEILGKSVRIIFSTLGVCIFYA
FGYMVLPLFAYFIRDWRMLLVALTMPGVLCVALWWFIPESPRWLISQGRFEEAEVIIRKA
AKANGIVVPSTIFDPSELQDLSSKKQQSHNILDLLRTWNIRMVTIMSIMLWMTISVGYFG
LSLDTPNLHGDIFVNCFLSAMVEVPAYVLAWLLLQYLPRRYSMATALFLGGSVLLFMQLV
PPDLYYLATVLVMVGKFGVTAAFSMVYVYTAELYPTVVRNMGVGVSSTASRLGSILSPYF
VYLGAYDRFLPYILMGSLTILTAILTLFLPESFGTPLPDTIDQMLRVKGMKHRKTPSHTR
MLKDGQERPTILKSTAF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009938|Solute carrier family 22 member 5 (SLC22A5)
ATGCGGGACTACGACGAGGTGACCGCCTTCCTGGGCGAGTGGGGGCCCTTCCAGCGCCTC
ATCTTCTTCCTGCTCAGCGCCAGCATCATCCCCAATGGCTTCACCGGCCTGTCCTCCGTG
TTCCTGATAGCGACCCCGGAGCACCGCTGCCGGGTGCCGGACGCCGCGAACCTGAGCAGC
GCCTGGCGCAACCACACTGTCCCACTGCGGCTGCGGGACGGCCGCGAGGTGCCCCACAGC
TGCCGCCGCTACCGGCTCGCCACCATCGCCAACTTCTCGGCGCTTGGGCTGGAGCCGGGG
CGCGACGTGGACCTGGGGCAGCTGGAGCAGGAGAGCTGTCTGGATGGCTGGGAGTTCAGT
CAGGACGTCTACCTGTCCACCATTGTGACCGAGCAAGACAGTGGGGCCTACAATGCTATG
AAAAACAGGATGGGAAAGAAGCCTGCTCTCTGCCTTCCTGCCCAGTGGAACCTGGTGTGT
GAGGACGACTGGAAGGCCCCACTCACAATCTCCTTGTTCTTCGTGGGTGTGCTGTTGGGC
TCCTTCATTTCAGGGCAGCTGTCAGACAGGTTTGGCCGGAAGAATGTGCTGTTCGTGACC
ATGGGCATGCAGACAGGCTTCAGCTTCCTGCAGATCTTCTCGAAGAATTTTGAGATGTTT
GTCGTGCTGTTTGTCCTTGTAGGCATGGGCCAGATCTCCAACTATGTGGCAGCATTTGTC
CTGGGGACAGAAATTCTTGGCAAGTCAGTTCGTATAATATTCTCTACGTTAGGAGTGTGC
ATATTTTATGCATTTGGCTACATGGTGCTGCCACTGTTTGCTTACTTCATCCGAGACTGG
CGGATGCTGCTGGTGGCGCTGACGATGCCGGGGGTGCTATGCGTGGCACTCTGGTGGTTC
ATCCCTGAGTCCCCCCGATGGCTCATCTCTCAGGGACGATTTGAAGAGGCAGAGGTGATC
ATCCGCAAGGCTGCCAAAGCCAATGGGATTGTTGTGCCTTCCACTATCTTTGACCCGAGT
GAGTTACAAGACCTAAGTTCCAAGAAGCAGCAGTCCCACAACATTCTGGATCTGCTTCGA
ACCTGGAATATCCGGATGGTCACCATCATGTCCATAATGCTGTGGATGACCATATCAGTG
GGCTATTTTGGGCTTTCGCTTGATACTCCTAACTTGCATGGGGACATCTTTGTGAACTGC
TTCCTTTCAGCGATGGTTGAAGTCCCAGCATATGTGTTGGCCTGGCTGCTGCTGCAATAT
TTGCCCCGGCGCTATTCCATGGCCACTGCCCTCTTCCTGGGTGGCAGTGTCCTTCTCTTC
ATGCAGCTGGTACCCCCAGACTTGTATTATTTGGCTACAGTCCTGGTGATGGTGGGCAAG
TTTGGAGTCACGGCTGCCTTTTCCATGGTCTACGTGTACACAGCCGAGCTGTATCCCACA
GTGGTGAGAAACATGGGTGTGGGAGTCAGCTCCACAGCATCCCGCCTGGGCAGCATCCTG
TCTCCCTACTTCGTTTACCTTGGTGCCTACGACCGCTTCCTGCCCTACATTCTCATGGGA
AGTCTGACCATCCTGACAGCCATCCTCACCTTGTTTCTCCCAGAGAGCTTCGGTACCCCA
CTCCCAGACACCATTGACCAGATGCTAAGAGTCAAAGGAATGAAACACAGAAAAACTCCA
AGTCACACAAGGATGTTAAAAGATGGTCAAGAAAGGCCCACAATCCTTAAAAGCACAGCC
TTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carnitine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cation</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>symporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modified amino acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of intestinal epithelial structure maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quorum sensing involved in interaction with host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-dependent organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0001018</id>
      <name>Solute carrier family 15 member 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16110</ref-id>
            <pubmed-id>10636865</pubmed-id>
            <citation>Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.</citation>
          </article>
          <article>
            <ref-id>A16239</ref-id>
            <pubmed-id>15567297</pubmed-id>
            <citation>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P46059" source="Swiss-Prot">
        <name>Solute carrier family 15 member 1</name>
        <general-function>Proton-dependent oligopeptide secondary active transmembrane transporter activity</general-function>
        <specific-function>Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.</specific-function>
        <gene-name>SLC15A1</gene-name>
        <locus>13q33-q34</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1-21
54-74
83-103
119-139
162-182
199-219
277-297
328-348
362-382
585-605
620-640
646-666</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.64</theoretical-pi>
        <molecular-weight>78805.265</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10920</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC15A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U13173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>773588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>984</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P46059</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S15A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Intestinal H(+)/peptide cotransporter</synonym>
          <synonym>Oligopeptide transporter, small intestine isoform</synonym>
          <synonym>PEPT1</synonym>
          <synonym>Peptide transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010713|Solute carrier family 15 member 1
MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDNLSTAIYHTFV
ALCYLTPILGALIADSWLGKFKTIVSLSIVYTIGQAVTSVSSINDLTDHNHDGTPDSLPV
HVVLSLIGLALIALGTGGIKPCVSAFGGDQFEEGQEKQRNRFFSIFYLAINAGSLLSTII
TPMLRVQQCGIHSKQACYPLAFGVPAALMAVALIVFVLGSGMYKKFKPQGNIMGKVAKCI
GFAIKNRFRHRSKAFPKREHWLDWAKEKYDERLISQIKMVTRVMFLYIPLPMFWALFDQQ
GSRWTLQATTMSGKIGALEIQPDQMQTVNAILIVIMVPIFDAVLYPLIAKCGFNFTSLKK
MAVGMVLASMAFVVAAIVQVEIDKTLPVFPKGNEVQIKVLNIGNNTMNISLPGEMVTLGP
MSQTNAFMTFDVNKLTRINISSPGSPVTAVTDDFKQGQRHTLLVWAPNHYQVVKDGLNQK
PEKGENGIRFVNTFNELITITMSGKVYANISSYNASTYQFFPSGIKGFTISSTEIPPQCQ
PNFNTFYLEFGSAYTYIVQRKNDSCPEVKVFEDISANTVNMALQIPQYFLLTCGEVVFSV
TGLEFSYSQAPSNMKSVLQAGWLLTVAVGNIIVLIVAGAGQFSKQWAEYILFAALLLVVC
VIFAIMARFYTYINPAEIEAQFDEDEKKNRLEKSNPYFMSGANSQKQM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010714|Solute carrier family 15 member 1 (SLC15A1)
ATGGGAATGTCCAAATCACACAGTTTCTTTGGTTATCCCCTGAGCATCTTCTTCATCGTG
GTCAATGAGTTTTGCGAAAGATTTTCCTACTATGGAATGCGAGCAATCCTGATTCTGTAC
TTCACAAATTTCATCAGCTGGGATGATAACCTGTCCACCGCCATCTACCATACGTTTGTG
GCTCTGTGCTACCTGACGCCAATTCTCGGAGCTCTTATCGCCGACTCGTGGCTGGGAAAG
TTCAAGACCATTGTGTCGCTCTCCATTGTCTACACAATTGGACAAGCAGTCACCTCAGTA
AGCTCCATTAATGACCTCACAGACCACAACCATGATGGCACCCCCGACAGCCTTCCTGTG
CACGTGGTGCTGTCCTTGATCGGCCTGGCCCTGATAGCTCTCGGGACTGGAGGAATCAAA
CCCTGTGTGTCTGCGTTTGGTGGAGATCAGTTTGAAGAGGGCCAGGAGAAACAAAGAAAC
AGATTTTTTTCCATCTTTTACTTGGCTATTAATGCTGGAAGTTTGCTTTCCACAATCATC
ACACCCATGCTCAGAGTTCAACAATGTGGAATTCACAGTAAACAAGCTTGTTACCCACTG
GCCTTTGGGGTTCCTGCTGCTCTCATGGCTGTAGCCCTGATTGTGTTTGTCCTTGGCAGT
GGGATGTACAAGAAGTTCAAGCCACAGGGCAACATCATGGGTAAAGTGGCCAAGTGCATC
GGTTTTGCCATCAAAAATAGATTTAGGCATCGGAGTAAGGCATTTCCCAAGAGGGAGCAC
TGGCTGGACTGGGCTAAAGAGAAATACGATGAGCGGCTCATCTCCCAAATTAAGATGGTT
ACGAGGGTGATGTTCCTGTATATTCCACTCCCAATGTTCTGGGCCTTGTTTGACCAGCAG
GGCTCCAGGTGGACACTGCAGGCAACAACTATGTCCGGGAAAATCGGAGCTCTTGAAATT
CAGCCCGATCAGATGCAGACCGTGAACGCCATCCTGATCGTGATCATGGTCCCGATCTTC
GATGCTGTGCTGTACCCTCTCATTGCAAAATGTGGCTTCAATTTCACCTCCTTGAAGAAG
ATGGCAGTTGGCATGGTCCTGGCCTCCATGGCCTTTGTGGTGGCTGCCATCGTGCAGGTG
GAAATCGATAAAACTCTTCCAGTCTTCCCCAAAGGAAACGAAGTCCAAATTAAAGTTTTG
AATATAGGAAACAATACCATGAATATATCTCTTCCTGGAGAGATGGTGACACTTGGCCCA
ATGTCTCAAACAAATGCATTTATGACTTTTGATGTAAACAAACTGACAAGGATAAACATT
TCTTCTCCTGGATCACCAGTCACTGCTGTAACTGACGACTTCAAGCAGGGCCAACGCCAC
ACGCTTCTAGTGTGGGCCCCCAATCACTACCAGGTGGTAAAGGATGGTCTTAACCAGAAG
CCAGAAAAAGGGGAAAATGGAATCAGATTTGTAAATACTTTTAACGAGCTCATCACCATC
ACAATGAGTGGGAAAGTTTATGCAAACATCAGCAGCTACAATGCCAGCACATACCAGTTT
TTTCCTTCTGGCATAAAAGGCTTCACAATAAGCTCAACAGAGATTCCGCCACAATGTCAA
CCTAATTTCAATACTTTCTACCTTGAATTTGGTAGTGCTTATACCTATATAGTCCAAAGG
AAGAATGACAGCTGCCCTGAAGTGAAGGTGTTTGAAGATATTTCAGCCAACACAGTTAAC
ATGGCTCTGCAAATCCCGCAGTATTTTCTTCTCACCTGTGGCGAAGTGGTCTTCTCTGTC
ACGGGATTGGAATTCTCATATTCTCAGGCTCCTTCCAACATGAAGTCGGTGCTTCAGGCA
GGATGGCTGCTGACCGTGGCTGTTGGCAACATCATTGTGCTCATCGTGGCAGGGGCAGGC
CAGTTCAGCAAACAGTGGGCCGAGTACATTCTATTTGCCGCGTTGCTTCTGGTCGTCTGT
GTAATTTTTGCCATCATGGCTCGGTTCTATACTTACATCAACCCAGCGGAGATCGAAGCT
CAATTTGATGAGGATGAAAAGAAAAACAGACTGGAAAAGAGTAACCCATATTTCATGTCA
GGGGCCAATTCACAGAAACAGATGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00854</identifier>
            <name>PTR2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>proton-dependent oligopeptide secondary active transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0001134</id>
      <name>Solute carrier family 15 member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16110</ref-id>
            <pubmed-id>10636865</pubmed-id>
            <citation>Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.</citation>
          </article>
          <article>
            <ref-id>A16239</ref-id>
            <pubmed-id>15567297</pubmed-id>
            <citation>Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16348" source="Swiss-Prot">
        <name>Solute carrier family 15 member 2</name>
        <general-function>Peptide:proton symporter activity</general-function>
        <specific-function>Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.</specific-function>
        <gene-name>SLC15A2</gene-name>
        <locus>3q13.33</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>58-78
88-108
115-135
140-160
184-204
218-238
296-316
344-364
381-401
568-588
612-632
644-664
675-695</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.38</theoretical-pi>
        <molecular-weight>81782.77</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10921</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC15A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S78203</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>999213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16348</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S15A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Kidney H(+)/peptide cotransporter</synonym>
          <synonym>Oligopeptide transporter, kidney isoform</synonym>
          <synonym>PEPT2</synonym>
          <synonym>Peptide transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037126|Solute carrier family 15 member 2
MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSY
YGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLV
YVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEER
TRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSK
IYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALT
RVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFD
FVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLN
LADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHS
VQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVG
EDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIED
IPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIV
LVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGNMI
KLETKKTKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010792|Solute carrier family 15 member 2 (SLC15A2)
ATGAATCCTTTCCAGAAAAATGAGTCCAAGGAAACTCTTTTTTCACCTGTCTCCATTGAA
GAGGTACCACCTCGACCACCTAGCCCTCCAAAGAAGCCATCTCCGACAATCTGTGGCTCC
AACTATCCACTGAGCATTGCCTTCATTGTGGTGAATGAATTCTGCGAGCGCTTTTCCTAT
TATGGAATGAAAGCTGTGCTGATCCTGTATTTCCTGTATTTCCTGCACTGGAATGAAGAT
ACCTCCACATCTATATACCATGCCTTCAGCAGCCTCTGTTATTTTACTCCCATCCTGGGA
GCAGCCATTGCTGACTCGTGGTTGGGAAAATTCAAAGTCCTATCATTGATCGGCCTGAGT
CTAATAGCTTTGGGGACAGGAGGCATCAAACCCTGTGTGGCAGCTTTTGGTGGAGACCAG
TTTGAAGAAAAACATGCAGAGGAACGGACTAGATACTTCTCAGTCTTCTACCTGTCCATC
AATGCAGGGAGCTTGATTTCTACATTTATCACACCCATGCTGAGAGGAGATGTGCAATGT
TTTGGAGAAGACTGCTATGCATTGGCTTTTGGAGTTCCAGGACTGCTCATGGTAATTGCA
CTTGTTGTGTTTGCAATGGGAAGCAAAATATACAATAAACCACCCCCTGAAGGAAACATA
GTGGCTCAAGTTTTCAAATGTATCTGGTTTGCTATTTCCAATCGTTTCAAGAACCGTTCT
GGAGACATTCCAAAGCGACAGCACTGGCTAGACTGGGCGGCTGAGAAATATCCAAAGCAG
CTCATTATGGATGTAAAGGCACTGACCAGGGTACTATTCCTTTATATCCCATTGCCCATG
TTCTGGGCTCTTTTGGATCAGCAGGGTTCACGATGGACTTTGCAAGCCATCAGGATGAAT
AGGAATTTGGGGTTTTTTGTGCTTCAGCCGGACCAGATGCAGGTTCTAAATCCCCTTCTG
GTTCTTATCTTCATCCCGTTGTTTGACTTTGTCATTTATCGTCTGGTCTCCAAGTGTGGA
ATTAACTTCTCATCACTTAGGAAAATGGCTGTTGGTATGATCCTAGCATGCCTGGCATTT
GCAGTTGCGGCAGCTGTAGAGATAAAAATAAATGAAATGGCCCCAGCCCAGCCAGGTCCC
CAGGAGGTTTTCCTACAAGTCTTGAATCTGGCAGATGATGAGGTGAAGGTGACAGTGGTG
GGAAATGAAAACAATTCTCTGTTGATAGAGTCCATCAAATCCTTTCAGAAAACACCACAC
TATTCCAAACTGCACCTGAAAACAAAAAGCCAGGATTTTCACTTCCACCTGAAATATCAC
AATTTGTCTCTCTACACTGAGCATTCTGTGCAGGAGAAGAACTGGTACAGTCTTGTCATT
CGTGAAGATGGGAACAGTATCTCCAGCATGATGGTAAAGGATACAGAAAGCAGAACAACC
AATGGGATGACAACCGTGAGGTTTGTTAACACTTTGCATAAAGATGTCAACATCTCCCTG
AGTACAGATACCTCTCTCAATGTTGGTGAAGACTATGGTGTGTCTGCTTATAGAACTGTG
CAAAGAGGAGAATACCCTGCAGTGCACTGTAGAACAGAAGATAAGAACTTTTCTCTGAAT
TTGGGTCTTCTAGACTTTGGTGCAGCATATCTGTTTGTTATTACTAATAACACCAATCAG
GGTCTTCAGGCCTGGAAGATTGAAGACATTCCAGCCAACAAAATGTCCATTGCGTGGCAG
CTACCACAATATGCCCTGGTTACAGCTGGGGAGGTCATGTTCTCTGTCACAGGTCTTGAG
TTTTCTTATTCTCAGGCTCCCTCTAGCATGAAATCTGTGCTCCAGGCAGCTTGGCTATTG
ACAATTGCAGTTGGGAATATCATCGTGCTTGTTGTGGCACAGTTCAGTGGCCTGGTACAG
TGGGCCGAATTCATTTTGTTTTCCTGCCTCCTGCTGGTGATCTGCCTGATCTTCTCCATC
ATGGGCTACTACTATGTTCCTGTAAAGACAGAGGATATGCGGGGTCCAGCAGATAAGCAC
ATTCCTCACATCCAGGGGAACATGATCAAACTAGAGACCAAGAAGACAAAACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00854</identifier>
            <name>PTR2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antibiotic transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dipeptide transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high-affinity oligopeptide transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0001066</id>
      <name>Solute carrier family 22 member 6</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15733</ref-id>
            <pubmed-id>10411577</pubmed-id>
            <citation>Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q4U2R8" source="Swiss-Prot">
        <name>Solute carrier family 22 member 6</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A6</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>10-30
136-156
165-187
191-213
225-245
249-269
338-358
369-389
396-416
426-446
456-475
485-505</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.78</theoretical-pi>
        <molecular-weight>61815.78</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>hROAT1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057039</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3831566</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q4U2R8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT1</synonym>
          <synonym>hPAHT</synonym>
          <synonym>hROAT1</synonym>
          <synonym>OAT1</synonym>
          <synonym>Organic anion transporter 1</synonym>
          <synonym>PAH transporter</synonym>
          <synonym>PAHT</synonym>
          <synonym>Renal organic anion transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037120|Solute carrier family 22 member 6
MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN
GGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI
VTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA
FAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV
AYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE
GAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL
QGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS
IVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE
LYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT
RQQQEHQKYMVPLQASAQEKNGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)
ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG
GTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC
ACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC
TTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG
GCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG
TACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC
CGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT
GGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC
TGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC
TTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG
CTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC
AAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC
TGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT
GCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT
GCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC
ATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG
GGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC
ACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG
AGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG
CGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG
AATGGACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-ketoglutarate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal tubular secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>